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Abstract
Major impediments to the full utility of current and potential drugs include issues of
resistance and delivery. To address these challenges, in this thesis two directions of research
were pursued: (1) the use of multivalent polymeric inhibitors to overcome drug resistance in
human and avian influenza and (2) low-viscosity, high-concentration protein suspensions for
therapeutic antibody, in particular monoclonal antibody (MAb), delivery.
(1) Influenza resistance to small molecule neuraminidase (NA) inhibitors is spreading.
Little emphasis, however, has been placed on alternative formulations of inhibitors. We
investigated the design of multivalent antivirals, wherein small molecule ligands of viral proteins
are conjugated via a linker to a linear polymeric backbone.
Unexpectedly, we found that a poly-L-glutamine bearing pendant zanamivir (ZA) groups
is at least as potent as those containing both ZA and sialic acid (SA). By examining the
structure-activity relationship of such monofunctional conjugates, we show that the most potent
one has 10% ZA attached to a neutral, high molecular weight backbone through a short alkyl
linker. Importantly, we also demonstrate that such a polymer conjugate entirely compensates for
weakened binding in and has 2,000-fold enhanced anti-viral potency against, ZA-resistant
strains.
We further evaluated this optimized inhibitor in vivo and observed that it is an effective
therapeutic of established infection in ferrets and reduces viral titers up to 190-fold when used as
a combined prophylactic/therapeutic in mice. Additionally, we see no evidence that the
conjugate stimulates an immune response in mice upon repeat administration.
(2) Typically, high doses of MAb therapeutics are required for clinical effect. Ideally,
these MAbs would be delivered by subcutaneous injection of a small liquid volume. Such highly
concentrated MAb solutions, however, are far more viscous than the 50 centipose (cP) permitted
by the FDA. We evaluated approaches to reduce formulation viscosity by forming protein
suspensions. Aqueous suspensions induced by poly(ethylene glycol), precipitating salts, or
ethanol actually increased viscosity. However, non-aqueous suspensions of amorphous antibody
powders in organic solvents that have s 1 hydrogen atom available for hydrogen-bonding,
exhibited up to a 38-fold decrease in viscosity.
Thesis Supervisor: Alexander M. Klibanov
Title: Firmenich Professor of Chemistry and Bioengineering
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Chapter 1: Influenza virus and current treatments
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A. Introduction
Epidemiology of Influenza
Yearly outbreaks of influenza affect approximately 20% of the world's
population'-4b and result in hundreds of thousands of deaths each year 2'. Population
growth and the convenience of international travel have contributed to the increased
incidence of influenza pandemics5 . Many of these pandemic viruses are human-
infectious reassortment strains that typically develop upon co-infection of a host species
with both an animal and a human strain '. Such inter-species reassortment is also known
as antigenic shift, and results in the expression of novel surface antigens to which the
human population is frequently serologically naive6 8 . These new variants heighten the
risk of severe illness and pandemic 6'8 . Additional variation arises from antigenic drift,
the result of drug and immune pressure and the rapid random mutation rate of RNA
viruses such as influenza9 . The accelerated emergence and recognition of drug-resistant
strains and, since 1997 the increased frequency of animal-to-human transmission of novel
and/or highly pathogenic strains7'8, underscore the necessity for anti-influenza therapies
to combat both avian viruses and drug resistance.
Biochemistry of Influenza Infection
Influenza virus belongs to the Orthomyxoviridae family of enveloped RNA
viruses. Three surface proteins integral to viral infection and replication have been
targeted by influenza treatments: major antigen hemagglutinin (HA), matrix protein 2
(M2), and minor antigen neuraminidase (NA).
Each subunit of the non-covalently linked HA homotrimer has a conserved
receptor-binding pocket that recognizes cell-surface sialic acids (SA)9 . Non-conserved
regions of HA determine increased binding affinity to either a-2,3- or a-2,6-linked SA,
10
found predominantly on avian or human cells, respectively6'10 '. Recently, however, a-
2,3-linked terminal SA was found to be more abundant in the human respiratory tract
than previously thought, perhaps explaining why avian-mammal re-assortment strains can
cause human epidemics10' 11.
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Figure 1-1. Infection cycle of influenza virus and points of action of current therapies. Virion
(A) displays HA (cone shaped spikes) and NA (stalks with bulbous heads) proteins. Low-affinity
HA interactions with cell surface SA lead to endocytosis (B). Upon acidification of the virion via
the M2 ion channel, HA irreversibly fuses with the endosomal membrane (C), releasing viral
nucleocapsid (D) for unpackaging. After transcription and protein synthesis, all components of
the new virion are assembled at the cell membrane (E). The virion buds from the cell membrane
and NA cleaves SA from the cell surface (F), releasing the viral particle to infect more cells.
Low affinity (Kd = 1 mM) high avidity interactions of cellular SA and viral HA
stimulate receptor-mediated endocytosis of influenza virions9,12 (Fig 1-1 B). Acidification
of the endosome by cellular H*-ATPases and the inside of the virion by the viral proton-
selective M2 ion channel, leads to irreversible structural changes in HA followed by
virus-endosome fusion9" 3 (Fig 1-1C). Subsequent release of viral nucleocapsids into the
cellular cytosol introduces viral RNA into the cell9 14 (Fig 1-ID).
At approximately four hours, after replication of viral RNA and viral particle
assembly at the apical surface of the infected cell, new virions bud from the cellular
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membrane6 '9 (Fig 1-1E). Viral enzyme NA cleaves the terminal a-ketosidic linkage
between SA and D-galactose or D-galactosamine on cell-surface glycoproteins and
glycolipids (Fig 1-IF). The influenza NA homotetramer preferentially catalyzes the
hydrolysis of a-2,3 and a-2,6 glycosidic bonds (Fig 1-2) through which virions are non-
covalently bound to a cell surface .
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Figure 1-2. Viral NA catalyzes ketosidic bond cleavage of terminal SA (1) through a covalent
intermediate (2) and oxocarbonium transition state (3) to generate free a-sialic acid with retention
of stereochemistry (4).
This enzymatic activity, in abolishing multivalent HA-SA interactions, speeds
release of new virions to infect adjacent cells, thus promoting multicycle infection9'10 ''.
NA activity also prevents virion aggregation during budding and degrades host mucins to
enable viral access to epithelial cell surfaces 9'1 '"8 . Whether these three actions are
critical to infection or whether they merely promote it is controversial'" 7-9 . All
influenza NA share eighteen highly conserved residues in the active site: eight functional
and ten structural20,21,22.
Antigenic classification of HA and NA proteins - i.e., HINI - is widely used to
discuss influenza viruses, and provides information on host species and potential
pathogenicity. Such categorization is based not on sequence homology, but on binding to
23subtype- specific anti-HA and anti-NA antibodies in a double immunodiffusion assay.
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HiNI and H3N2 strains are the most common human infectious strains that cause the
bulk of morbidity during yearly outbreaks, and are always targeted in annual
6,24vaccinations
Treatments for influenza
Currently, only two treatment modalities are available for influenza infection:
immunization and small molecule inhibitors. Prophylactic seasonal immunization with a
vaccine against three subtypes of major surface antigen HA is up to 70% effective in the
non-elderly and immune-competent populations 24 but relies on accurate prediction of
future circulating strains. Antigenic shift or inaccurate strain selection make the vaccine
even less efficacious. Though they are costly, have many side effects, and have a small
therapeutic window, broader-spectrum small molecule inhibitors targeting the M2 and
NA proteins of all influenza strains have been developed to prevent and control disease
when the vaccine is least effective24 -26
Inhibition of the M2 ion channel by the adamantane class of drugs prevents
release of RNA from viral nucleocapsid complexes, thus halting replication' (Fig 1-iC).
Recently, however, the FDA has recommended against use of the these inhibitors as most
circulating influenza A viruses are now resistant to them 27,28, and resistant mutations have
even been identified in highly pathogenic H5N1 strains isolated from treated patients29.
Fewer resistant strains of influenza are identified after treatment with the NA
inhibitors zanamivir (5, ZA; RelenzaTm ) and oseltamivir (6, Tamiflu TM), two SA
transition-state analogs (Fig 1-3). Resistance to oseltamivir is now commonly identified
in both treated patients and circulating strains4 ,2 7 ,3 0- 32 though the prevalence of such
resistance varies from season to season28 . Mutations conferring resistance to ZA appear
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less frequently. Though such mutations reduce enzymatic activity, their effects on viral
fitness (i.e. ability to infect, replicate, and re-infect) are unresolved33 34
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Figure 1-3. Chemical structures of NA inhibitors. Approved inhibitors include analogs of
the NA-induced SA transition state (3) including ZA (5), oseltamivir (6), and prodrug
laninamivir (7). Peramivir (8) has characteristics of both 5 and 6. Novel analogs of the at-
anomer of SA (4) including 2a-3,-4-guanidino-difluorosialic acid (9) have been recently
identified as highly effective covalent NA inhibitors.
Though there is a high degree of conservation in and around the NA active site,
mutations conferring resistance to oseltamivir and ZA typically arise at structural
residues in a subtype specific manner, commonly at H274 in NI enzymes (oseltamivir-
resistant) and at R292 or E 119 in N2 enzymes (oseltamivir- and ZA-resistant, or just ZA-
resistant, respectively) 21,31 . The highly potent NA inhibitors laninamivir (7) and
peramivir (8) (Fig 1-3) are still undergoing FDA approval but were widely used during
the 2009 pandemic under temporary emergency authorization 36. However, Cross-
resistance to NA-inhibitor-resistant strains has been observed with these newer drugs as
they too inhibit NA 36'37 . The search for small molecule inhibitors designed to circumvent
or prevent drug resistant mutations is ongoing against current31,38-42 and novel2 8 ,43 -45
targets. For example, a recent report identified a new class of mechanism-based SA
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analogs such as 9 that show no cross-resistance, effectively inhibiting drug-resistant NA
mutants up to 40-fold better than ZA by trapping covalent intermediate 2 (Figure 1-2)42.
Work in our lab and others has shown that macromolecules - as opposed to small
molecules - are typically more potent inhibitors of influenza infection. These inhibitors
comprise recombinant proteins7.46 , and derivatized polypeptides 47' 48 or synthetic
49-52polymers4. In the coming chapters we build on previous work with derivatized
synthetic polymers and explore the benefits of such an alternative approach, including
facile structure optimization, broad-spectrum inhibition of drug-susceptible and drug-
resistant strains, and in vivo prophylactic and therapeutic efficacy.
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Chapter 2: Polymer-attached zanamivir inhibits drug-resistant strains of influenza A
virus
Much of the work described in this chapter was/will be published in the following
manuscripts:
Weight AK, Haldar J, Alvarez de Cienfuegos L, Gubaerva LV, Tumpey TM, Chen J,
Klibanov AM, Attaching zanamivir to a polymer markedly enhances its activity against
drug-resistant strains of influenza A virus. 2011, JPharm Sci, 100, (3), 831-835.
Weight AK, Belser JA, Tumpey TM, Chen J, Klibanov AM, Zanamivir conjugated to
poly-L-glutamine is much more active against influenza viruses in mice and ferrets than
the drug itself. 2013, JPharm Sci. Submitted.
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A. INTRODUCTION
Drug resistance is a rapidly evolving threat to global human health. Though the
prevalence of drug-resistant mutations varies seasonally, current treatments are often
rendered entirely ineffective1-3. Therapeutics that inhibit all strains of influenza - both
drug-susceptible and drug-resistant - are urgently needed, and small-molecule discovery
has not yet successfully addressed the issue.
Macromolecular and multivalent inhibitors of influenza
Macromolecular inhibitors - either proteins or synthetic polymers - offer a
promising alternative paradigm. In particular, they hold promise as broad-spectrum
inhibitors that can address issues of drug resistance. For example, the fusion sialidase
DAS 181 (FludaseTM) removes cell-surface sialic acid (SA) in the airways to prevent the
viral attachment to cellular hemagglutinin (HA) receptors that initiates infection 46 .
Though low-level resistance to DAS 181 has been observed, it appears to be reversible
upon removal of treatment7.
Another way to prevent these numerous HA-SA interactions is to harness that
same multivalency - the interaction of multiple copies of a ligand (i.e., SA) with multiple
copies of a target protein (i.e., HA) - in a synthetic inhibitor (Fig 2-1). By attaching
analogs of SA9-11 or sialyloligosaccharides 12 to polymer scaffolds, such conjugates can
mimic a cell surface, "trapping" a virus via multivalent binding before infection occurs.
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Figure 2-1. Schematic illustration of proposed multivalent inhibition. (A) A flexible polymer
scaffold (curved black line) bearing pendant groups (gray ovals) attached through flexible linkers
(gray sticks) (B) participates in a multivalent interaction with receptors on the surface of a viral
particle.
Indeed, such multivalent inhibitors showed enhanced inhibition of virion binding
to cell-surface SA in an erythrocyte sedimentation assay9 -11 '13 and inhibition of viral
infection in cell culture' 4 . Both the polyacrylamide/polyacrylate 9" and polystyrene'
backbones primarily used in those studies, however, are not amenable to drug
development due to in vivo acrylamide toxicity'16,17, in vitro polyacrylamide toxicity at
17,181inhibitory concentrations '', and poor water solubility". Sialyloligosaccharides
conjugated to biocompatible scaffolds such as dendrimeric polyethylenimine19 and poly-
L-lysine 20, or linear poly-L-glutamic acid18,20,21 showed up to 20-fold enhanced inhibition
of infection. Analogously, multivalent NA inhibitors composed of poly-L-glutamine22 23
or oxidized dextran24 bearing pendant zanamivir (ZA) groups demonstrated increased
potency in cell culture compared to small molecule ZA itself.
Another potential benefit of polymeric inhibitors is the coupling of multivalency
and combination therapy, which is known to reduce the emergence of drug-resistant
pathogens25 . Previously in our lab, a bifunctional inhibitor - a single polymer bearing
multiple different ligands of viral proteins, i.e., SA and ZA - that has multiple modes of
22
A
action, was shown to synergistically enhance efficacy compared to a polymer with ZA
alone26 . Such inhibitors, however, were based on the biodegradable but potentially
immunogenic hydrolyzed poly(isobutylene-alt-maleic anhydride) backbone (PIBMA)27.
Although multivalent ZA-containing inhibitors possess enhanced potency against select
wild-type human strains of influenza virus2 2 ,2 3 ,2 6 , their efficacy against a range of
subtypes and drug sensitivities has not been explored.
Project preview
Expanding upon the aforementioned studies, in this chapter we 1) show that
across numerous influenza subtypes and strains, monofunctional ZA-derivatized
polymers are at least as efficacious as bifunctional inhibitors, 2) optimize the percent ZA,
linker group, and polymer backbone of such a monofunctional inhibitor through in vitro
structure activity relationship (SAR) studies, and 3) demonstrate that attaching ZA to a
polymer backbone can overcome both oseltamivir and ZA resistance in not only human
but also avian strains. Additionally, in Chapter 3, we present preliminary in vivo data
assessing efficacy and immunogenicity of the optimized ZA-derivatized inhibitor
identified herein.
B. RESULTS AND DISCUSSION
Bifunctionally derivatized polypeptides show neither additive nor synergistic
inhibition
First, to explore the benefits of multivalent ZA-derivatized polymers, we selected
poly-L-glutamate as the starting material for synthesis of our inhibitors. Poly-L-
glutamate, which is commercially available in a range of molecular weights, has been
used safely in vivo 2 8 ,2 9 and is readily modified synthetically.
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Figure 2-2. Scheme of synthetic route to ZA-derivatized poly-L-glutamines. (A) a-SA-derivative
10 and ZA-derivative 11 were reacted with (B) hydroxybenzotriazole activated poly-L-glutamate.
The reaction was quenched with ammonium hydroxide to give ZA-derivatized poly-L-glutamines
(12a-12j) with the indicated mole percents of SA (p), unmodified side chain (q), and/or ZA (r).
Extent of derivatization was determined by IH-NMR with an error of h 2 mole percent.
Next, linker groups were chosen, through which small molecules were conjugated
to the polymer backbone. SA was modified at the anomeric carbon which is the only
solvent-exposed functional handle. X-ray crystal structures of ZA in the NA active site
showed that the 7-OH group is solvent exposed, pointing out and away from the
enzyme 3 1 . Masuda et al.'s SAR study of derivatives of ZA found that modification of
this 7-OH group with alkyl ether substituents less than ten carbon atoms in length
(nominally some 16 A) had no negative effects on antiviral activity compared to ZA
itself23. Therefore, we initially selected a linker of only six carbon atoms (Fig 2-2
compound 11). As expected, the introduction of an alkyl carbamate linker group did not
drastically affect the anti-viral or NA inhibitory activity; the inhibitory potencies of 11
and ZA were within an order of magnitude of each other (Table 2-1).
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Previous efforts showed that inhibition of the HINI strain Yamagata was most
effective with 10 mole % loading of ZA on poly-L-glutamine 23 ; other multivalent systems
reached a plateau in efficacy between 10% and 30% modification 1,1,32,33 . Thus, we
selected 10% loading for our initial experiments as well, and synthesized water-soluble
polymeric derivatives of ZA in which the drug was conjugated to poly-L-glutamate
through a hexyl linker group. The reaction was quenched with ammonium hydroxide2 3,26
(Fig 2-2) and conjugation was confirmed and quantified by 'H-NMR. We then assayed
the resultant inhibitor using the "gold-standard" viral plaque reduction assay.
Unlike other methods, this cell-based assay directly measures only infectious
virions 34,35 . The plaque reduction assay begins with a pre-incubation step of a constant
amount of virus with varying amounts of inhibitor. This mixture is used to inoculate a
cell monolayer that after infection is covered with a porous agar overlay. As infected
cells die, they are trapped by the agar to form an opaque region - a plaque - visible to the
eye. Fifty-percent maximal inhibitory concentrations (IC 50 ) were determined from
comparison of treated and untreated cells.
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Table 2-1. Antiviral activities of ZA (5), its monomeric derivative 11, and poly-L-glutamine
derivatized with 10 mol % 11 (12b), against three influenza A viruses as determined in the
plaque reduction assay.
Inhibitor IC50 (nM ZA)a
WSN (HINI) Victoria (H3N2) Wuhan (H3N2)
ZA (5.4 2.4) x 103  (4.8 1.5) x 104 (2.3 1.6) x 104
ZA-linker (1.0 0.17) x 103 (1.3 0.32) x 104 (4 .3 0.20) x 105
PGN-ZA (1.8 0.41) x 102  74 ±8.5 21 ±7.3
a All values were determined from experiments run at least in triplicate. The IC50 values
are expressed in concentrations of ZA, whether free or conjugated to poly-L-glutamine.
The IC50 values for bare poly-L-glutamine ranged from 2 to 8 mM (based on the monomer
concentrations) as compared with 0.2 to 40 [M for 12b, thus demonstrating that the
polymer itself has no appreciable antiviral activity. Inhibitors were present during pre-
incubation and infection, thus the reported IC50 values reflect inhibition of infection. p-
values were calculated at a 95% confidence interval. There is a statistically significant
difference in IC50 values between ZA and 11, and 11 and 12b for all viruses.
We tested our initial 1 0%-derivatized inhibitor against three strains of influenza
virus: A/WSN/33 (WSN), A/Victoria/3/75 (Victoria), and clinically isolated
A/Wuhan/359/95 (Wuhan) (Table 2-1). Against the HINi WSN strain we observed a 6-
fold reduction in IC50 for polymer-attached ZA compared to the small molecule (Table 2-
1). Comparably, Masuda et al observed a 18-fold reduction for a similar conjugate
against the HINI Yamagata strain2 3 . For the H3N2 strains, however, the observed
improvement was orders of magnitude greater: 180-fold and 20,000-fold for Victoria and
Wuhan, respectively (Table 2-1).
Next, we investigated whether adding a second, unique pendant group to the
polymer backbone affected the inhibitory potency of our original ZA-derivatized poly-L-
glutamine 12b. Numerous studies have modified the polymer backbone with groups that
had non-specific interactions with the viral surfaceo,1 9,3 3 . Here, we added SA as a second
pendant group with specific binding to HA. Combination therapy, targeting multiple
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steps fo the infection cycle, may enhance potency compared to 12b. We synthesized
three bifunctional polymers that did not exceed approximately 20% total derivatization
(Fig 2-2) - still within the previously observed optimal efficacy rangeo1,i,23,32,33 - and
tested them against WSN, Victoria, and Wuhan strains. From the results presented in
Table 2-2, we can make several important conclusions. First and as expected, when
compared to small molecules, bifunctional polymeric inhibitors 12a, 12d, and 12g were
far more potent: up to 47,000-fold more than small molecule SA analog 10 and 20,000-
fold more than ZA analog 11. Second, the presence of up to ~15% 11 in a bifunctional
polymer enhanced efficacy up to 70-fold compared to the corresponding monofunctional
polymers derivatized with SA analog 10. Third, the presence of up to ~15% 11 in a
bifunctional polymer afforded no statistically significant benefits compared to the
corresponding monofunctional polymers modified with ZA analog 11. Fourth, a physical
mixture of two monofunctional polymers - one bearing 10 and one 11 - had statistically
equivalent potency to the 11-derivatized component alone.
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Table 2-2: Antiviral activities of monomeric derivatives 10 and 11, and polymeric inhibitors
(12a-12i) containing varying mole percents of 10, 11, or both, against three influenza A viruses
as determined in the plaque reduction assay
Inhibitor % Derivatizationa IC50 (nM zanamivir)
10 11 WSN (HIN1) Victoria (H3N2) Wuhan (H3N2)
10 N/A N/A >> 106 >> 106 >> 106
tic N/A N/A (1.0 ± 0.17) x 103 (1.3 ±0.32) x 104 (4.3 0.20) x 105
12a 9 8 (1.8 ± 0.83) x 102 (1.4 ± 0.50) x 102 30 ± 7.0
12b 0 11 (1.8 ±0.41) x 102  74 ±8.5 21 ±7.3
12c 10 0 (2.4 ±0.21) x 103  (3.4 ±0.21) x 103  (3.0 ±0.90) x 102
12d 6 17 (2.2 1.5) x 102 n.d. (1.7 0.48) x 102
12e 0 16 (1.9 0.92) x 102  n.d. (3.4 ±1.0) x 102
12f 5 0 (1.6 0.80) x 104  n.d. (2.8 1.3) x 103
12g 15 5 (1.3 0.83) x 103  n.d. (1.9 ± 0.98) x 102
12h 0 5 (5.4 2.1) x 102 n.d. (1.8 0.50) x 102
12i 16 0 (3.5 0.50) x 103 n.d. (2.4 ± 0.70) x 102
12b+12c 10 11 90 ±15 n.d. 20 ±2.1
a Percent derivitization with small molecules 10 and 11 was determined by 'H-NMR with an error of ± 2
mole percent.
b Inhibitors were present in pre-incubation and infection steps, thus the reported IC50 values reflect
inhibition of infection. p-Values were calculated at a 95% confidence interval. Comparison of all
bifunctional inhibitors to their ZA-derivatized monofunctional counterparts demonstrated no statistically
signifcant differences in ICo. Comparison of all bifunctional inhibitors to their SA-derivatized
monofunctional counterpartes demonstrated statistical significance in all instances except for 12d against
Wuhan strain. Comparison of the physical mixture 12b+12c to 12b alone showed no statistically
significant diference in IC50.
' The introduction of a linker group in ZA-derivative 11 did not drastically affect IC50 against the avian
strain TKY, either.
Previous work in our lab, however, showed that bifunctional PIBMA-based
polymeric inhibitors synergistically inhibit Wuhan strain 26 , but not other strains (personal
communication). The final observations above - that monofunctional inhibitors
derivatized with 11 are at least as effective as covalent or physical bifunctional mixtures
- both 1) indicated that any previously detected synergism is highly strain- and polymer-
dependent and 2) defined the scope of our subsequent studies, which focused on the
optimization of monofunctional polypeptides bearing ZA derivatives for inhibition of a
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wide range of influenza A viruses.
ZA-derivatized polymers are broad-spectrum inhibitors that overcome drug
resistance
In addition to WSN, Victoria, and Wuhan strains, we tested monofunctional
polymeric inhibitor 12b against an avian A/turkey/MN/833/30 (TKY) strain and three
drug-resistant strains carrying mutations at position 119: two in vitro selected ZA-
resistant avian strains TKY El 19D and TKY El 19G36 and clinically isolated oseltamivir-
resistant Wuhan El 19V, which retains transmissibility37 . Polymeric inhibitor 12b was
240-fold more potent than 11 against avian strain TKY, extending the trend we observed
with human strains (Fig 2-3). Importantly, both oseltamivir- and ZA-resistant mutants
were also far more susceptible to polymeric 12b than to small-molecule inhibitor 11; we
observed a 6000-fold improvement against Wuhan E119V mutant and up to a 2000-fold
greater enhancement against zanamivir-resistant TKY mutants (Fig 2-3). Maximal
improvements for experimental small molecule inhibitors, however, have not exceeded
1000 times against oseltamivir-resistant influenza strains38 and 250 times against ZA-
resistant ones3 9 to date.
29
100,000-
10,000V4
* 1,000
100
A
10 
Wuhan Wuhan TKY TKY TKY
E119V E119D E119G
Figure 2-3. Anti-viral activity enhancements of polymeric 12b over small-molecule 11 against
wild-type and drug-resistant influenza strains. ZA-based inhibitors were present during pre-
incubation and infection, thus the underlying IC50 values reflect inhibition of infection. The
reported antiviral activity enhancements reflect experiments run at least in triplicate, except for
the TKY mutants which were only run in duplicate due to the large quantities of 11 required.
Fifty percent inhibition was not reached for the ZA-resistant mutants, even at millimolar
concentrations of 11; thus the actual enhancements are at least those indicated. Differences in the
underlying IC50 values are statistically significant with p <0.005.
We expanded our investigation by examining whether the amount of 11
conjugated to poly-L-glutamine affects the inhibitory potency of monofunctional
inhibitors. Optimal percent conjugation for multivalent systems may differ between
previously examined wild-type strains1,2332,33 and the drug-resistant mutants in which
we are interested. Polymeric 12b (10% of 11) was up to 16-fold more potent than either
12h or 12j (5% and 20%, respectively) against ZA-sensitive strains WSN, Wuhan,
Wuhan E119V, and TKY (Fig 2-4). Importantly, 12b was also up to 8-fold more potent
against ZA-resistant TKY strains.
Overall, the observation of the same optimal degree of loading for all the viral
strains tested suggests that beyond a certain point, the benefits of multivalency are
counteracted by steric effects. Presumably, even when binding affinity is reduced as in
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drug-resistant strains, high ligand occupancy interferes with inhibitor binding and/or
causes steric clash between ligands that force the polymer into a less active conformation.
100000
10000
M 12h 12b 11 12j
* 100**
IS100
10
WSN Wuhan Wuhan
E119V
*
m
TKY TKY TKY
E119D E119G
Strain
Figure 2-4. Antiviral activities of monofunctional polymers derivatized with 5% (12h), 10%
(12b), or 20% (12j) of 11, against human and avian, drug-susceptible and drug-resistant strains,
as determined in the plaque reduction assay. All values were determined from experiments run
at least in triplicate. The IC50 values are expressed in concentrations of ZA whether free or
conjugated to poly-L-glutamine. Inhibitors were present during pre-incubation and infection,
thus the underlying IC 5o values reflect inhibition of infection. The IC5 o values for bare poly-L-
glutamine ranged from 2 to 10 mM (based on the monomer concentrations), demonstrating that
the polymer itself has no appreciable antiviral activity.
We subsequently pursued SAR studies of the linker group and polymer backbone
of 10 mole % ZA-polymer conjugates. We examined two alternative linker structures of
approximately the same length as our original alkyl linker (10 A): (i) a flexible and
hydrophilic ethylene glycol and (ii) a rigid hydrophobic phenyl (Fig 2-5A, compounds 13
and 14).
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Figure 2-5. (A) Synthetic scheme of linker attachment and chemical structures of ZA derivatives
with different linkers (11, 13, and 14) for attachment to (B) polymer scaffolds with different
electrostatic charges (neutral, negative, and zwitter-ionic) (12, 15, and 16) to give polymer
conjugates with (C) varying linker groups (12b, 12k, and 12m) and (D) charges on the polymer
backbone (12b, 15a, 16a).
We tested these ZA analogs in the plaque reduction assay against three strains of
influenza virus: WSN, Wuhan, and avian TKY. For all three strains, IC50 values showed
that 11 was the most potent inhibitor by up to 57-fold over flexible and hydrophilic
analog 13 and 76-fold over rigid analog 14 (Fig 2-6). When attached to the poly-L-
glutamine backbone, compound 12b - the polymeric conjugate of 11 (Fig 2-5C) - was as
good as or better than both 12k and 12m (poly-L-glutamine conjugates of 13 and 14,
respectively) against WSN and Wuhan viruses, and at least 10-fold more potent against
TKY virus (Fig 2-6). Thus we selected ZA analog 11, which is flexible and moderately
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hydrophobic, for subsequent SAR studies of polymer properties. We did not aggressively
pursue longer linkers because 1) previous studies by Masuda et al 3 showed that 7-0-
substituents more than ten carbons atoms in length reduced ZA efficacy and 2) ZA binds
at the easily accessible head of the NA protein40 , thus only a short linker should be
necessary to reach to the binding site. While a longer linker would still increase effective
ligand concentration at the viral surface, it may introduce additional steric or entropic
costs, potentially counteracting some of the benefit of multivalency.
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Figure 2-6. Antiviral activities of ZA analogs 11, 13, and 14 (A), and their polymer-attached
derivatives 12b, 12k, and 12m (B) against three strains of influenza A virus, as determined by the
plaque reduction assay. Reported values were determined from experiments run at least in
triplicate. IC50 values are expressed as concentrations of ZA, whether free or conjugated to
polymer. Inhibitor was present during preincubaiton and infection, thus the reported IC5o values
reflect inhibition of infection. The IC50 values for unmodified poly-L-glutamine ranged from 2 to
14 mM (on a monomer basis).
Next, we examined the effect of length and charge of the polymer backbone on
antiviral activity. Specifically, we used a scaffold of poly-L-glutamate of either 3-15 (20-
100 repeating units) or 50-100 kDa (330-660 repeating units), and to it conjugated 10
mole percent of 11. Subsequently, we modified the glutamate side chains with ammonia
or choline groups to impart a neutral or zwitter-ionic state, respectively (15a and 16a, Fig
33
2-5D). We assessed the inhibitory potency of these six polymeric conjugates in the
plaque reduction assay with Wuhan, TKY, and ZA-resistant TKY E119D strains.
Conjugate 16a, regardless of molecular weight or virus strain, had the highest IC5 0 value
(Fig 2-7). For negatively charged conjugate 15a, the low molecular weight inhibitor had
an IC 50 up to 4-fold lower than the high molecular weight conjugate. Conversely, high
molecular weight 12b was up 15-fold more potent than the low molecular weight variant
against all three viruses, and up to 75-fold more potent compared to corresponding
charged analogs 15a and 16a (Fig 2-7). Also, polymer structure did not have a greater
effect on IC5o when binding of 11 is weaker (i.e., for TKY El 19D strain).
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Figure 2-7. IC50 values for low-molecular-weight (3-15 kDa; black bars) and high-molecular-
weight (50-100 kDa; white bars) conjugates 12b, 15a, and 16a against (A) Wuhan, (B) TKY, and
(C) TKY El 19D isolates of influenza A virus. IC50 values, reported as nanomolar concentrations
of ZA, were determined using the plaque reduction assay with inhibitor present during
preincubation and infection. Thus, IC50 values reflect inhibition of infection. IC50 values of bare
backbones 12, 15, and 16 ranged from 2 to 39 mM, compared to at least 85 pM for drug
conjugates. Thus, the polymers themselves had no appreciable antiviral activity. * p < 0.05, ** p
< 0.01, and *** p < 0.001 were determined by a two-tailed Student's t-test. All reported values
are the mean ± SD of at least three independent measurements.
In their study of sialic acid-derivatized polyacrylamides that bind the HA of
influenza virus, the Whitesides group reported that addition of charge to the backbone -
either positive or negative - decreased binding strength in an erythrocyte sedimentation
assay 9' 10. Our results suggest that the same trend applies to NA-binding poly-L-
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glutamate-based conjugates of 11 in the plaque reduction assay. Changes in polymer
conformation due to the addition of charge 0 would be particularly relevant with peptide-
based scaffolds and could affect the ability of the drug conjugate to inhibit viral infection.
Mechanisms of multivalent inhibition
To gain further quantitative mechanistic insights, we determined inhibition
constants Ki for both 11 and 12b, using drug-resistant strains and the corresponding wild-
type Wuhan and TKY viruses in a whole-virus NA inhibition assay. There are several
important conclusions gleaned from the data presented in Table 2-3. First, 11 binds at
least two orders of magnitude weaker to ZA-resistant strain TKY E119D and El 19G (last
two lines of Table 2-3) than to the wild-type and oseltamivir-resistant strains. This is in
good agreement with the original literature report on these strains36 . Second, ZA-
derivatized 12b is a substantially more potent enzyme inhibitor than small molecule ZA.
Third, while binding affinity enhancements resulting from polymer conjugation are
relatively modest for wild-type and oseltamivir-resistant strains, ZA-resistant TKY
mutants bind 12b 2000 times stronger than 11. Because of this strengthened binding, the
ZA-resistant mutants become as sensitive to 12b (in contrast to 11) as the other strains
(Table 2-3). Presentation of ZA on the polymer entirely compensates for weakened
binding in ZA-resistant TKY strains.
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Table 2-3. Inhibition constants (Ki) of viral NAs by small-molecule (11) and polymeric (12b)
ZA derivatives against both wild-type and drug-resistant human and avian influenza A strains.
Strain Ki (nM ZA)a,b
11 12b
Wuhan 3.1 1.0 0.93 0.12
Wuhan EI19V 1.9 0.81 0.90 0.10
TKY 4.6 0.92 0.27 ±0.16
TKY E119D 800 150 0.37 0.12
TKY E119G 370 20 0.13 0.054
a All values were determined from experiments run at least in triplicate. The Ki values are
expressed in concentrations of ZA, whether free or conjugated to poly-L-glutamine. Even at 10
mM, bare poly-L-glutamine showed no inhibition of NA activity, thus the polymer itself has no
appreciable enzyme inhibitory activity. For conditions, see Materials and Methods.
b Enhancement of 12b over 11 is statistically significant for all strains except Wuhan El 19V
(p=0.0508).
Multivalent drug species, such as 12b, tend to exhibit better virus inhibition as a
result of entropic and steric effects, and increased affinity"'10'41. There should be similar
rotational and translational entropic costs for the initial interaction with viral surface
proteins for both free and polymer-bound ZA. Polymer-bound ZA, however, should have
lower costs for subsequent interactions, thereby providing entropic benefits of
multivalency 41. Flexible linkers and polymers such as that employed so far in this study,
can promote improved ligand-protein binding by reducing steric obstacles and increasing
effective ligand concentration 42 (as is schematically illustrated in Figure 2-1).
Surprisingly, however, our lab has shown that 12b has an additional synergistic
mechanism of action that enhances eficacy: inhibition of early intracellular stages of
infection4 3 . Specifically, in the presence of 12b but not ZA, we saw 1) an accumulation
of endocytosed virions co-localized with cellular acidic compartments and 2) an
inhibition of HA fusion with cell membranes at fusion-inducing low pH43 . These
observations suggested that 12b interferes with trafficking and HA-mediated virus-
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endosome fusion.
Previously, we observed no significant strain or subtype specificity for the
interaction of 12b with viral NAs as would occur during viral budding and aggregation
(Table 2-3). Next, we sought to determine if 12b inhibitory activity was strain or subtype
specific in either the early stages or across all stages of infection (including but not
limited to inhibition of NA activity). To this point, inhibitor has been present in the
plaque assay during pre-incubation and infection, inhibiting only early events such virus-
endosome fusion (-1-1 h) (Fig 2-8). Additionally, here we added ZA or 12b to the agar
overlay to examine for inhibition of virion release and multicycle infection as well (- 1-72
h).
+ Inhibitor A Figure 2-8. Experimental design for theplaque reduction assay of inhibition at (A)
early stages (-1 - 1 h) of infection and (B)
- Oh 1 h 72 h throughout (-1 - 72 h) infection. Inhibitor ist t added to a virus solution and pre-incubated
Infection Overlay Analysis for 1 h. After infection, the virus and
inhibitor mixture is removed and an agarose
+ Inhibitor B overlay containing (A) PBS or (B) inhibitor
V V is placed on the cells. Analysis of plaque
| I | number is performed at 72 h.
-1lh Oh 1lh 72 h
Infection Overlay Analysis
As expected for ZA - whose only mechanism of action is direct inhibition of late-
stage NA activity - inclusion in the agar enhanced IC50 at least 100-fold for all strains
(Table 2-4). For 12b against H3N2 strains, we saw at most a 3-fold improvement in IC 50
(Table 2-4) compared to values for only the initial stages of infection. For HINI and
H4N2 strains, however, we saw up to a 72- and greater than 180-fold enhancement in
efficacy, respectively, when inhibitor 12b was present during all stages of the infection
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cycle. This suggests that 12b has a greater effect on virus-endosome fusion in H3N2
strains, perhaps because H3N2 viruses have a more pH-sensitive HA fusion process.
These results underscore the need to study many strains of influenza virus.
Table 2-4. IC50 values for inhibition of influenza A viruses in the plaque reduction assay by ZA
and polymer 12b during all stages . The polymeric inhibitor was included during pre-incubation
and infection steps of the assay. 12b was either absent (-1-1 h) or present (-1-72 h) in the agar
overlay to assay for early stage infection or multi-cycle infection, respectively.
IC50 (nM zanamivir)a
Strain Subtype Polymeric 12b Small molecule 11
-1-1 h -1-72 h -1-1 h -1-72 h
(early stages) (all stages) (early stages) (all stages)
Wuhan 21 ± 7.3 8.7 0.70 (4.3 ± 0.20) x 105 (3.6 0.45) x 102
Wuhan EI19V H3N2 51 ±5.0 17 6.2 (3.1 ±0.10) x 105 (2.2 1.7) x 102
Victoria 74± 8.5 30 8.0 (1.3 ±0.32) x 104 (2.6 0.47) x 103
WSN HIN (1.8 0.41) x 102  2.5 1.0' (1.0 ±0.17) x 10
3  58± 11
PR8 (3.0 ±0.89) x 102  1.7 1.2 (4.5 1.5) x 103  (8.8 ±0.20) x 102
TKY (1.8 ±0.20) x 102  2.1 0.44 (4.3 ±1.1) x 104  (2.5 ±0.12) x 102
TKY E119D H4N2 (1.7 0.83) x 103  34 16 >3.6 x 106  (2.2 1.1) x 104
TKY E119G (3.6 ±1.3) x 103  20 4.9 >3.6 x 106  (7.1 0.14) x 104
a Reported values are the average of triplicate measurements unless otherwise indicated. Horizontal lines
within the table separate subtypes. There is a statistically significant difference between IC50 values obtained
at -1-1 h and -1-72 h for both 11 and 12b against all strains, with p-values ranging from 0.0001 to 0.0479.
b Reported IC50 value is the average of two measurements.
Conclusion
Overall, conjugate 12b with its long, neutral backbone and short, flexible linker is
the most potent inhibitor of the derivatives examined herein. We have also demonstrated
broad-spectrum efficacy and a noteworthy ability of 12b to overcome drug resistance by
enhancing ZA binding strength. In vitro efficacy, however, does not always translate to
animal models of disease. In Chapter 3, we examine efficacy and immunogenicity of
conjugate 12b in the mouse and ferret models of influenza infection.
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C. MATERIALS AND METHODS
Chemicals
Poly-L-glutamic acid sodium salt (molecular weight = 3,000 - 15,000 and
50,000- 100,000 Da) and all other chemicals and solvents were purchased from Sigma-
Aldrich Chemical Co (St. Louis, Missouri, USA) unless otherwise indicated.
Synthesis and characterization
ZA was obtained from BioDuro (Beijing, China). ZA derivative 11 (Fig 2-2) was
synthesized from combined literature procedures44'45 as described previously26 . Sialic
acid derivative 10 (Fig 2-2) was prepared from combined literature procedures 46-48 as
described previously 26, except for linker attachment in which silver zeolite was used in
place of mercury salts (see 18 below). Polymer conjugates 12a-12j were prepared using
a modified literature procedure2 2 (Fig 2-2). Bare poly-L-glutamine (12) was synthesized
analogously. All intermediates and target derivatives were analyzed by 1H-NMR.
Content of SA and ZA in polymeric inhibitors was quantified by 'H-NMR.
Methyl-2-(4-tert-butoxycarbonylglycylamidobenzyl)-5-acetamido-4,7,8,9-tetra-O-
acetyl-3,5-dideoxy-2-oxo-D-glycero-D-galacto-2-nonulopyranosonate (18, an
intermediate in the synthesis of 10; Fig 2-9) was synthesized using a combination of
literature procedures 49-51. To a reaction vessel protected from light were added solid
chlorinated sialic acid (0.1 mmol, (1-(3-acetamido-4-acetoxy-6-chloro-6-
(methoxycarbonyl)tetrahydro-2H-pyran-2-yl)propane- 1,2,3-triyl triacetate)), (4-tert-
butoxycarbonylglycylamido)benzyl alcohol 48 (0.048 mmol), powdered 4A molecular
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sieves, and 35% silver zeolite freshly prepared as previously described5 2 and dried
overnight under nitrogen at 150*C. The vessel was purged and CH 2Cl 2 (10 mL) was
added. The mixture was vigorously stirred under nitrogen at RT for 30 hours. After
diluting with DCM (10 mL) the mixture was filtered through a celite pad and solvent was
evaporated. Purification on a silica gel (230-400 mesh) column with EtOAc:Toluene 1:1
yielded the title compound in 20% yield (overall yield for both anomers was very high at
70%).
AcO OAc AcO OAc O O NH
Silver 0 HO
zeolite
AcHN 0 COOMe CH2go AcHN 0 COOMe
AcO Mol sieve AcO
17 RT 30 h 18
alpha >> beta beta > alpha
Figure 2-9. Reaction scheme for silver-mediated linker attachment to chlorinated sialic acid. SA
chlorination with HCl produces mostly the c-anomer (17). A subsequent Koenigs-Knorr-type
reaction results largely in inversion at the glycosidic bond (18). The c-anomer of 18 is produced
because there is no ester on the adjacent carbon to act as an intramolecular nucleophile and
promote 100% inversion.
'H-NMR (CDCl 3) 6 (400 MHz) - 1.40 (9H, s, C(CH 3)3), 1.85 (4H, m, NCOCH, H-3ax),
2.0 (3H, s, OCOCH), 2.15 (6H, s, 2 x OCOCH), 2.70 (lH, dd, H-3 eq), 3.55 (3H, s,
OCH), 3.80 (1H, dd, H-6), 3.85-4.00 (4H, m, OCH2, COCH2NH), 4.05-4.15 (2H, m, H-
9a, H-5), 4.33 (lH, dd, H-9b), 4.70 (lH, ddd, H-4), 5.30 (1H, dd, H-7), 5.35-5.45 (1H, m,
H-8), 5.70 (1H, d, NHCOCH3), 7.20 and 7.35 (4H, 2d, aromatic).
3-Acetamido-2-(1-(((2-(2-aminoethoxy)ethyl)carbamoyl)oxy)-2,3-dihydroxypropyl)-4-
guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid (13) was synthesized using a
modified literature procedure 4 4' 4 5 with tert-butyl-(2-(2-aminoethoxy)ethyl)carbamate
(ChemPep, Wellington, FL) to introduce the linking group. Subsequent
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reduction/deprotection with triphenyl phospine/triethylamine/H 20 and guanidinylation
with NN'-bis-t-butoxycarbonyl-1H-pyrazole-1-carboxamidine of intermediates were
performed as previously described44 45 , with modification to the purification schemes.
For both intermediates, purification was done using a reverse-phase silica plug (Sep Pak
C18 cartridge vac 6cc, Water, Milford, MA). Intermediates were loaded in water and 1:4
H20:methanol, respectively. Product was eluted with 12 mL of water followed by either
15% acetonitrile or 40% methanol, respectively. BOC-deprotection was performed as
previously described 44'4 5 to give compound 5. 1H NMR (D2 0) 6 (500 MHz) - 1.85 (3H, s,
CH3CONH), 3.05-3.25 (4H, m, -NHCH2CH20CH2CH 2NH 2), 3.40 (1H, dd, H-9a), 3.50
(2H, m, -NHCH2CH 20CH2CH2NH2), 3.60 (1H, d, H-9b), 3.65 (2H, m, -
NHCH2CH 20CH2CH2NH 2), 3.95 (1H, m, H-8), 4.05 (1H, t, H-5), 4.35 (1H, d, H-4), 4.45
(1H, d, H-6), 4.90 (1H, d, H-7), 5.95 (1H, d, H-3).
3-Acetamido-2-(1-(((4-(aminomethyl)phenyl)carbamoyl)oxy)-2,3-dihydroxypropyl)-4-
guanidino-3,4-dihydro-2H-pyran-6-carboxylic acid (14) was synthesized analogously to
13 above using tert-butyl-4-aminobenzylcarbamate to introduce the linker group. ' H
NMR (D20) 6 (500 MHz) - 1.85 (3H, s, CH3CONH), 3.45 (1H, q, H-9a), 3.60 (1H, d, H-
9 b), 4.10-4.20 (2H, m, H-5 and H-8), 4.35-4.45 (3H, m, PhCH2NH 2 and H-4), 4.50 (1H,
d, H-6), 5.0 (1H, d, H-7), 5.85 (1H, d, H-3), 7.25-7.35 (4H, m, aromatic).
Polymer conjugates 12k and 12m were synthesized analogously to 12b2 2 . 'H NMR
(D2 0) 8 (500 MHz) - for 12k: 1.8-2.1 (5H, m, 2H polymer and CH3CONH), 2.1-2.4 (2H,
d, 2H polymer), 3.0-3.2 (4H, m, NHCH 2CH 20CH2CH 2NH2), 3.35-3.45 (2H, m,
NHCH2CH20CH2CH 2NH 2), 3.45 (1H, dd, H-9b), 3.55 (1H, d, H-9a), 3.6 (2H, m,
NHCH 2CH20CH2CH2NH 2), 3.95 (11H, m, H-8), 4.05-4.25 (2H, s, 1H polymer and H-5),
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4.45 (1H, d, H-4), 4.55 (1H, d, H-6), 5.7 (lH, s, H-3). For 12m: 1.9-2.1 (5H, m, 2H
polymer and CH3CONH), 2.2-2.4 (2H, d, 2H polymer), 3.5 (1H, q, H-9a), 3.6 (1H, dd, H-
9 b), 4.1-4.35 (9H, m, 4H polymer, H-4, H-5, H-8, PhCH2NH2), 4.5 (1H, d, H-6), 5.7 (1H,
d, H-3), 7.3 (4H, m, 4H aromatic)
Conjugate 15a and scaffold 15. Conjugate 15a was synthesized analogously to 12b2 2
using 3 mL of 0.1 M NaOH to quench the polymer conjugation reaction for 48 h at RT.
Un-derivatized 15 was synthesized by quenching benzotriazole-activated poly-L-
glutamate with an excess of 0.1 M NaOH. After quenching, both reactions were diluted
with distilled water and buffer exchanged into the same at least four times using an
Amicon Ultra Centrifugal Filter with an Ultracel regenerated cellulose membrane (15
mL, 15 kDa MWCO) at 4,000 x g before lyophilization. 1H NMR (D20) 8 (500 MHz) -
For 15a: 1.1-1.4 (8H, m, -NHCH 2(CH2) 4CH 2NH2), 1.7-2.4 (7H, m, 4H polymer and
CH3CONH), 2.8-3.05 (4H, m, -NHCH2(CH 2)4CH2NH2), 3.5 (1H, dd, H-9b), 3.6 (1H, d,
H-9a), 3.8 (2H, m, H-5, H-8), 4.1-4.25 (1H, s, 1H polymer), 4.45 (1H, d, ZA), 4.55 (1H,
d, H-6), 5.0 (1H, d, H-7), 5.75 (1H, s, H-3). For 15: 1.7-2.3 (4H, m, 4H polymer), 4.2
(1H, s, 1H polymer).
Conjugate 16a and scaffold 16. Attachment of 11 to the activated polymer scaffold was
performed analogously to 12b2 2 . After 4 h, the reaction was cooled on an ice bath. Solid
N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.72 mg, 0.0142 mmol,
1.2 equiv) was added to the reaction mixture, which was subsequently purged with argon
gas. A solution of 4-dimethylaminopyridine (0.072 mg, 0.00059 mmol, 0.05 eq) in DMF
(15 tL) was then added, and the mixture stirred for 5 min. A pre-cooled solution of
choline chloride (6.59 mg, 0.0472 mmol, 4 equiv) in formamide (240 tL to give a final
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concentration of formamide in reaction of 30% v/v) was then added dropwise. The
reaction was stirred on ice for 16 h and allowed to warm to RT overnight. Bare 16 was
synthesized by quenching benzotriazole-activated poly-L-glutamate with choline chloride
in formamide as described above. After quenching, both reactions were diluted with
distilled water and buffer exchanged into the same at least four times using an Amicon
Ultra Centrifugal Filter with a regenerated cellulose membrane (15 mL, 15 kDa MWCO)
at 4,000 x g before lyophilization. 1H NMR (D2 0) 8 (500 MHz) - For 16a: 1.2-1.5 (8H,
m, -NHCH2(CH2) 4CH 2NH 2), 2.0-2.8 (7H, m, 4H polymer and CH3CONH), 2.9-3.05 (4H,
m, -NHCH2(CH 2)4CH2NH 2), 3.2 (911, s, -N(CH3)3), 3.5 (1H, dd, H-9a), 3.55 (1H, d, H-
9 b), 3.7 (2H, s, -CH2N-) 4.05 (2H, m, H-8 and H-5), 4.1-4.3 (211, 1H polymer and H-4),
4.5 (1H, d, H-6), 4.55 (2H, s, -CH20-), 5.65 (11H, s, H-3). For 16: 2.0-2.8 (4H, m, 4H
polymer), 3.25 (9H, s, -N(CH3)3), 3.8 (211, s, -CH2N-), 4.15-4.4 (11H, s, 1H polymer),
4.65 (2H, s, CH2 0-).
Influenza Virus
Plaque-purified influenza A/WSN/33 (WSN; HINI) and A/Victoria/3/75
(Victoria; H3N2) were cultured in E4HG medium from MDCK cells (ATCC; Manassas,
VA) for 2-3 days, clarified, and filtered through a 0.2-rim filter to remove aggregates.
Influenza virus strains A/Wuhan/359/95 (Wuhan; H3N2), A/turkey/MN/833/80 (TKY;
H4N2), and A/turkey/MN/833/80/E119D drug-resistant mutant (TKY E119D) were
obtained from the Centers for Disease Control and Prevention (Atlanta, GA), and
propagated as previously described 26 . Sucrose-gradient purified influenza A/PR/8/34
(PR8; HINI) was obtained from Charles River Labs in HEPES-saline buffer
(Wilmington, MA) and diluted with PBS (pH 7.2) before use. Titers were determined by
serial titration in the plaque assay53. Stocks of influenza A/Nanchang/933/95 (Nanchang)
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H3N2 virus were grown in the allantoic cavities of 10-day-old embryonated hens' eggs at
34'C for 48-72 h. Pooled allantoic fluid was clarified by centrifugation and stored at -
70"C.
Plaque Reduction Assay
Plaque assays were performed in 12-well plates using a modified literature
procedure26 ,34. For the pre-incubation step, 55 tL of virus diluted in PBS (-800 pfu/mL)
was incubated with an equal volume of inhibitor solution in PBS (serially 10-fold diluted)
for 1 h at room temperature. After washing, confluent MDCK cell monolayers were
infected at room temperature for 1 h with 100 VL of the virus-inhibitor mixture. The
inoculum was removed by aspiration, and the cells were overlaid with 1 mL of plaque
medium [2X F12 medium, 0.0 1% DEAE-dextran, 0.1% NaHCO 3, 100 units/mL of
penicillin G, 100 tg/mL of streptomycin, 4 tg/mL of trypsin, and 0.6% purified agar
(L28; Oxoid Co., Basingstoke, UK)]. Plaques were counted after 3 to 4 days of
incubation at 37o C.
Neuraminidase Inhibition Assay
Neuraminidase inhibition assays were performed using a modified literature
procedure5 4 . Briefly, whole virus (20 tL) and inhibitor dilutions (15 tL) were incubated
at room temperature for 1 h. Following addition of fluorogenic substrate 4-
methylumbelliferyl-a-D-N-acetylneuraminic acid (final concentration of 2 iM was 5- to
10-fold lower than the Km of the enzymes), generation of 4-methylumbelliferone was
monitored at 5 min intervals for 1 h. Substrate fluorescence was inhibitor dose-
dependent. Values of Ki were determined using nonlinear regression in KaleidaGraph.
Statistical Analysis
Unpaired two-tailed Student's t-test was performed using Prism 6 software at
95% confidence interval.
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Chapter 3: Polymer-attached zanamivir is both an effective prophylactic and therapeutic in vivo
Most of the work presented in this chapter will be published in the following manuscript:
Weight AK, Belser JA, Tumpey TM, Chen J, Klibanov AM, Zanamivir conjugate to poly-L-
glutamine is much more active against influenza viruses in mice and ferrets than the drug itself.
2013, JPharm Sci. Submitted.
Dr. Jessica Belser performed work with ferrets.
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A. Introduction
Influenza is a persistent and constantly evolving threat to global human health. Despite
annual vaccinations, hundreds of millions of people are infected and hundreds of thousands die
from the infection each year' 2 . The utility of currently approved antivirals, including the NA
inhibitors TamifluTM (oseltamivir) and RelenzaTM (zanamivir; ZA), continues to diminish as they
are rendered ineffective by viral mutations3 4 . Although the search for new small-molecule
inhibitors is ongoing5-8, identifying compounds with high potency both in vitro and in vivo has
been only minimally successful.
In addition to enhanced binding seen in soluble protein or whole-virus studies of SA-
containing polymeric inhibitors of hemagglutinin (HA) 9-13, some sialoligosaccharide-
polyacrylate conjugates have also shown efficacy in vivo in mice1 4'15 . Analysis of disease
symptoms, lung histology, and mortality showed benefits of the polymeric species compared to
untreated mice 4 ". Interestingly, quantification of viral load was not directly assayed in any
study. While promising, these studies were performed with polymers that, depending on uptake
and metabolism, are potentially toxic and immunogenic16-18. Similarly, a ZA-containing polymer
has only been assessed for its impact on survival19 . All of these studies, however, failed to
investigate un-adapted human influenza strains, a necessary corollary to in vitro studies with
such viruses. Here, we examine viral loads in 1) infected mice and 2) human influenza-infected
ferrets after treatment with biocompatible ZA-derivatized poly-L-glutamine inhibitor 12b.
Further, we assess the immunogenicity of conjugate 12b in mice.
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B. Results and Discussion
Polymeric inhibitor 12b is an effective prophylactic and therapeutic drug in the mouse and
ferret models of infection
As described in Chapter 2, we have identified conjugate 12b - poly-L-glutamine
containing 10 mole percent of 7-0-alkyl-carbamate ZA analog 11 (Fig 3-1) - as a drug candidate
that fills two unmet needs: it (i) is a potent inhibitor of drug-resistant strains of influenza viruses
(Chapter 2) and (ii) has two modes of action inhibiting both neuraminidase activity and virus-
endosome fusion20 . Overall, conjugate 12b with its long neutral backbone and short flexible
linker was the most potent inhibitor of the derivatives examined (see Chapter 2). Herein, we
have examined in vivo polymer-attached ZA 12b (Fig 2-2) in the mouse and ferret models of
influenza infection.
NH(CH 2)6\H3  H2N 0
HO OH HO Of CF3COO-
0 OHO 0 HO 0 H r
AcNH COO AcNH / COO
Oy'
HN HN
>=fH2 >= tH2 ggH2N H2N 0 11
5 11 12b: x:y = 11:89
12j: x:y = 21:79
Figure 3-1. Chemical structures of ZA (5), ZA analog 11, and poly-L-glutamine-attached 11 (polymeric
12b).
First, we selected to study three virus strains known to replicate in animals: WSN and
A/PR/8/34 (PR8) strains in mice and A/Nanchang/933/95 (Nanchang) in ferrets. We determined
that Nanchang was an appropriate model strains because its growth was inhibited in the plaque
assay by ZA and 12b to a similar extent as other strains within the same subtype.
We then tested 12b in a mouse model of influenza virus infection against WSN and PR8
strains. Briefly, mice were given intranasal doses of polymeric 12b, ZA, or PBS (as a control),
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immediately followed by intranasal infection. At 6, 24, and 48 h post-infection (p.i.), the mice
were again given 12b, ZA, or PBS intranasally (Fig 3-2A). Viral load was subsequently
measured in whole-lung homogenates at 72 h p.i. Inhibitor doses were selected to be the lowest
effective dose of ZA (determined by dose response studies with WSN and PR8 strains) and the
equivalent molar dose of 12b (in terms of ZA).
We determined viral titers from lung homogenates of WSN-infected mice using the
plaque assay. Untreated mice had high titers of 107 pfu/mL (Fig 3-2B). When treated with ZA,
the titers dropped 20-fold. Upon treatment with a molar equivalency of polymeric conjugate 12b,
the titers plummeted 190-fold, whereas no decrease was detected from treatment with poly-L-
glutamine (12) alone. Thus 12b is some 10-fold more potent than ZA at inhibiting WSN
infection in mice.
For mice infected with PR8, we analyzed lung homogenates using qRT-PCR. Here,
treatment with 12b reduced viral load 11-fold more than that with ZA (Fig 3-2C), which
correlates well with the above-referenced WSN study. Across both influenza strains and both
analytical methods, therefore, we observed the same trend: polymeric conjugate 12b was an
order of magnitude more potent than ZA.
In mice, intranasal delivery of fluids post-infection with influenza virus - as we did in
this study - has been shown to exacerbate the disease.2 1  This fact can render experimental
compounds less potent because they must inhibit significantly higher viral titers than presumed.
Consequently, our data may even underestimate the potency of polymeric inhibitor 12b in the
mouse model.
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Next, we determined the efficacy of 12b in ferrets because this animal model of influenza
infection is known to accurately reflect virus infectivity and antiviral activities in humans2 2 2 3 .
Ferret and humans share similar lung physiology and distribution of viral receptors' 22 '2 3 . On day
0, ferrets were infected with Nanchang virus, a clinically relevant human influenza strain.
Beginning one day p.i., the ferrets were dosed daily with 12b, ZA, or PBS (as a control) (Fig 3-
3A). A nasal wash was collected from each ferret on days 2, 4, 6, and 8 to measure viral titer.
On day 2 p.i., the ferrets given equimolar doses of ZA or 12b (in terms of ZA) exhibited similar
reductions in titer of 38- and 30-fold, respectively, compared to the PBS-treated group (Fig 3-
3B). Treatment with 12b continued to reduce viral titers significantly compared to PBS controls
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0.01 were determined by two-tailed Student's t-test.
All reported values are the mean of at least three
independent measurements.
- 30- and 20-fold on days 4 and 6 p.i., respectively, - whereas treatment with ZA did not (Fig 3-
3B). Thus, polymeric conjugate 12b is a more effective therapeutic agent than ZA in this highly
relevant ferret model of influenza infection.
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Figure 3-3. (A) Experimental design to determine
A therapeutic efficacy of 12b in ferrets. (B) Viral titers
in nasal washings of ferrets infected with Nanchang
strain of influenza virus. Groups were treated with
vehicle (PBS; black bars; n=6), or equimolar doses of
ZA (grey bars, n=6) or 12b (white bars, n=6).
B Statistically significant differences between PBS
control and treated groups are represented by * p <
0.05 and ** p < 0.01 as determined by two-tailed
N P1S Student's t-test. Mean values ± SEM represent
ZA triplicate measurements.
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Polymeric inhibitor 12b does not stimulate an immune response in mice
Finally, we examined whether repeated dosing with 12b stimulates an immune response,
which could render 12b ineffective. Although small molecules, such as ZA, do not typically
elicit an antibody response, as part of a polymeric conjugate they can behave as haptens and
become immunogenic 24-26. To assess this possibility, we challenged mice intranasally for four
days with a daily dose of PBS (as a control) or 40 [tg of 12b. This dose was 1) 40 fold higher
than that used to inhibit virus infection in mice and 2) a dose similar to that used for modeling
reactive airway disease and thus presumably high enough to stimulate inflammatory and immune
responses in the lung27 . Ten days after the first administration serum samples were collected. To
increase the probability of antibody induction, after four weeks the mice were re-challenged for
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three days with PBS or 40 tg of 12b daily, and sera were again collected ten days later. Using
11, 12, and 12b as capture antigens in an ELISA assay, we tested for the presence of specific
IgG, IgM, and IgA in the serum samples. Only a background level of immunoglobulin was
detected in the mice given 4b before, after primary, and after secondary challenge, the same as in
control mice given PBS (Table 3-1).
Table 3-1. Drug-specific serum immunoglobulin ELISA titers from mice treated with high-dose 12b or
PBS (as a control) were measured pre-challenge ("Pre-"), 10 days after primary challenge ("Primary"),
and 10 days after secondary challenge ("Secondary").
Capture Time point Reciprocal specific antibody titersa
antigen (relative to IgG IgM IgA
challenges) PBS 12b PBS 12b PBS 12b
Pre- <20 <20 <20 <20 <20 <20
ZA Primary <20 <20 <20 <20 <20 <20
Secondary <20 <20 20 20 <20 <20
Pre- <20 <20 20 20 20 20
12 Primary <20 <20 20 20 20 20
Secondary <20 <20 20 20 20 20
Pre- <20 <20 <20 <20 <20 <20
12b Primary <20 <20 20 <20 20 <20
Secondary <20 <20 20 20 20 20
Pre- <20 <20 40 40 20 20
12j Primary <20 <20 40 20 20 20
Secondary <20 <20 40 40 20 20
a The titers are reported as the reciprocal of the least dilute sample with signal 2-fold above background and
are the average of at least two measurements of each sample within each group (n=3). Serum dilutions were
1:20, 1:40, and 1:100.
Sometimes, however, the more hapten that is present in the capture antigen, the more
sensitive the ELISA to hapten- or conjugate-specific antibodies 2 4 ,2 8 ,2 9 . Even when 12j - with 20
mole-percent 11 (Fig 3-1) - was used as a capture antigen, again only background levels of
immunoglobulin were detected in 12b-treated mice, as in PBS-treated mice (Table 3-1). Thus,
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upon repeated challenge with a dose 40-fold higher than that used in the aforementioned
infection studies, no neutralizing antibodies against 12b or any of its components were detected.
Conclusion
In summary, we have demonstrated herein that optimized polymeric drug species 12b is
an efficacious inhibitor of influenza infections in the respiratory tracts, reducing viral titers up to
190-fold in vivo and without stimulating an immune response. These results, coupled with other
beneficial properties of 12b - namely, multiple modes of inhibition2 0 and efficacy against drug-
resistant virus strains (Chapter 2) - make it a promising inhibitor of influenza infection for
further development.
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C. Materials and Methods
Influenza viruses
Plaque-purified influenza A/WSN/33 (WSN; HiNI) was cultured in E4HG medium from
MDCK cells (ATCC; Manassas, VA), clarified, and filtered through a 0.2-[tm filter to remove
aggregates. Influenza virus strains A/Wuhan/359/95 (Wuhan; H3N2), A/turkey/MN/833/80
(TKY; H4N2), and A/turkey/MN/833/80/E119D drug-resistant mutant (TKY E119D) were
obtained from the Centers for Disease Control and Prevention (CDC) (Atlanta, GA) and
propagated as previously described3 0. Sucrose-gradient purified influenza A/PR/8/34 (PR8;
HINi) was obtained from Charles River Laboratories in HEPES-saline buffer (Wilmington,
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MA) and diluted with PBS (pH 7.2) before use. Viral titers were determined by serial titration in
the 12-well format plaque assay. Stocks of influenza A/Nanchang/933/95 (Nanchang) H3N2
virus were grown in the allantoic cavities of 10-day-old embryonated hens' eggs at 34'C for 48-
72 h. Pooled allantoic fluid was clarified by centrifugation and stored at -70'C. Fifty percent egg
infectious dose (EID5o) titers were determined by serial titration of virus in eggs and calculated
by the method of Reed and Muench.
Ethics statement
All mouse procedures were approved by the MIT Committee on Animal Care under
protocol #0310-027-13. Animal studies were performed in accordance with the IACUC
guidelines at the CDC under protocol #2195TUMFERC-A3: "Studies on the Pathogenesis and
Transmission of Recombinant Influenza Viruses in Ferrets".
Mouse experiments
Male Balb/C mice at 8 weeks (Jackson Laboratories, Bar Harbor, ME) were used in this
study. They were anesthetized with intraperitoneal avertin injection and dosed intranasally in
one nostril with a 25 tL solution of either PBS (vehicle control), ZA, 12, or 12b. Within 10 min,
mice were then infected with 25 tL of virus solution in PBS (1,000 pfu/mouse) delivered in the
same nostril. At 6, 24, and 48 h post-infection (p.i.), mice were again given PBS, ZA, 12, or
12b.
Inhibitor doses were 0.028 tmol/kg for ZA, an equimolar dose of 12b (0.028 imol/kg on
a ZA basis; 0.24 tmol/kg on a monomer basis), and 11 tmol/kg 5 (40-fold molar equivalency on
a monomer basis). Group sizes were: PBS - 6 mice, 12 - 3 mice, 12b - 4 mice, and mock
infection - 3 mice. For WSN-infection, 5 mice were given ZA. For PR8-infection, 6 mice were
given ZA. Animals were euthanized with CO 2 at 72 h post-infection (p.i). Whole mouse lung
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was harvested, rinsed in ice-cold homogenization buffer (50 mL of IX PBS plus 150 tL of 35%
BSA and 500 tL of a solution of 10,000 IU/ml penicillin G and 10,000 mg/mL streptomycin (JR
Scientific, Woodland, CA)), flash-frozen on dry ice in 1 mL of ice-cold homogenization buffer,
and stored at -80'C until processing.
For PR8-infected mice, lungs were homogenized using a Branson Sonifier 250 with a /8"
tapered tip probe (Branson Ultrasonics, Danbury, CT). Total RNA was extracted from 170 tL
of clarified lung homogenate using the PureLink Viral RNA/DNA Kit (Invitrogen, Carlsbad,
CA) according to manufacturer's instructions. Viral RNA was eluted in Tris-EDTA buffer (pH
8.0) and stored at -80*C. Quantification of viral RNA was performed using the RNA Ultrasense
One-step qRT-PCR System (Invitrogen) according to manufacturer's instructions after treatment
with RNase-free DNase (Ambion, Austin, TX). Primer and probe to detect the encoding region
for the M1 matrix protein were used at concentrations of 1,900 nM and 754 nM, respectively, in
a total reaction volume of 40 tL. Sequences of influenza A-specific primers and probe (IDT,
Coralville, IA) were previously established33 . A Roche LightCycler@ instrument was used for
real-time reverse-transcriptase PCR using the following program: 45'C for 30 min, 95C for 2
min, and 50 cycles of 95*C for 5 sec, 55'C for 10 sec, and 72'C for 10 sec. All samples and a
standard curve of serially diluted un-passaged virus were run on the same reaction plate. Levels
of viral RNA in lung homogenates3 4 are expressed as threshold cycle (CT), determined using
LightCycler@ 480 System software v. 1.5. To confirm that any residual polymer in
homogenates did not interfere with RNA extraction, a sample of stock virus and a sample of
homogenate from an untreated mouse were spiked with 5 before extraction and PCR. A standard
curve of the spiked virus and CT value of the spiked homogenate were in agreement with that of
the un-passaged virus. Thus, the observed CT values reflect robust purification.
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For WSN-infected mice, lungs were homogenized using a Dounce homogenizer on ice.
Viral titers of WSN in clarified murine lung homogenates were determined by 12-well format
plaque assay and expressed in pfu/mL30 ,31 ,35 . To exclude the possibility that the reduced titers
measured in treated groups were a result of residual ZA or 12b in lung homogenates, one
uninfected mouse was dosed with each inhibitor. Lung homogenates from these mice were
mixed in equal volume with that of infected but untreated (PBS control) mice. No significant
difference in virus titer was observed; the reduction in titer seen with treated mice does indeed
reflect in vivo inhibition.
Immune response studies were performed with 8-week old male Balb/C mice. Mice were
split into two groups of four, anesthetized with intraperitoneal avertin and challenged with 40 tL
of PBS or 40 tL of 1 mg/mL 12b at 0, 6, 24, and 48 h. After 4 weeks, mice were re-challenged
with three administrations of 40 tL of PBS or 40 tL of 1 mg/mL 12b. Serum samples were
collected "pre-challenge" from a tail-vein 3 weeks before initial challenge. "Primary challenge"
and "secondary challenge" samples were collected 10 days after initial challenge and secondary
challenge. Serum samples were separated using BD Microtainer serum separator tubes (Becton
Dickinson, Franklin Lakes, NJ) and stored at -80'C.
ELISA
ELISA to determine total and specific immunoglobulin levels in mouse serum was
performed according to a modified literature procedure using Costar Universal Bind plates
(Corning, Tewksbury, MA)20 . Antibody pairs and standards (mouse IgG, IgM, and IgA) and
TMB substrate were used directly from Ready-Set-Go Mouse Ig kits (eBioscience, San Diego,
CA). For detection of 12b-, 12-, or ZA-specific antibodies by ELISA, 50 tL of 0.01 mg/mL 12b
or 12, and 50 VL of 0.1 mg/mL 11 were incubated overnight at 4*C. Capture antibodies were
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incubated according to manufacturer's instructions. For washing, 1% PBST (1% BSA (w/v) and
0.05% (v/v) Tween 20 in PBS) were used. Blocking (4 h, RT) and serum dilutions (100 tL total
incubation volume) were performed with 2% PBST (2% BSA (w/v) and 0.05% (v/v) Tween 20
in PBS). After washing five times, HRP-conjugated antibody was incubated at RT for 3 h, and
detection performed as per manufacturer's instruction. Serum from all experimental mice plus
serum from an untreated but WSN-infected mouse (positive control collected at 2.5 weeks p.i.)
were included on each plate. Sensitivity of the assay was 1.5 ng/mL for IgG, 0.7 ng/mL for IgM,
and 0.7 ng/mL for IgA.
Ferret experiment
Adult male Fitch ferrets, five months of age (Triple F Farms, Sayre, PA), serologically
negative by hemagglutination-inhibition assay for currently circulating influenza viruses, were
used in this study. Six ferrets per group were anesthetized with an intramuscular injection of a
ketamine hydrochloride (24 mg/kg)-xylazine (2 mg/kg)-atropine (0.05 mg/kg) cocktail and
infected intranasally with Nanchang virus at 105 EID50 in a final volume of 1 mL of PBS. Ferrets
were sedated by Ketamine before intranasal delivery of 500 tL (250 tL per nostril) of 6 tmol/kg
bodyweight of 12b in PBS; six control ferrets received vehicle (PBS) only. Ferrets receiving
treatment with ZA were given 0.7 tmol/kg bodyweight in PBS administered intranasally. Ferrets
received daily dosing of PBS, 12b, or ZA over a period of eight days beginning 24 h p.i. Ferrets
were monitored daily for changes in body weight and temperature, as well as clinical signs of
illness. Body temperatures were measured using an implantable subcutaneous temperature
transponder (BioMedic Data Systems, Seaford, DE). Virus shedding was measured in nasal
washes collected on days 2, 4, 6, and 8 p.i. from anesthetized ferrets as previously described36.
Virus titers in nasal washes were determined in eggs and expressed as EID5 o/mL.
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Statistical analysis
Unpaired two-tailed Student's t-test was performed using Prism 6 software.
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Chapter 4: Reducing the viscosity of highly concentrated antibody formulations
Most of the work presented in this chapter will be published in the following manuscript:
Srinivasan C, Weight AK, Bussemer T, Klibanov AM, Non-aqueous suspensions of antibodies
are much less viscous than equally concentrated aqueous solutions. 2013, Pharm Res. Accepted.
Dr. Charu Srinivasan performed work with PEG- and salt-induced y-globulin suspensions and
collaborated on work with y-globulin suspensions in aqueous and non-aqueous organic solvents.
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A. Introduction
Monoclonal antibody (MAb) therapeutics are increasingly common in clinical practice1,
generally demonstrating high specificity and selectivity and low toxicity when humanized or
fully human' 5*. They are frequently used to treat cancer, autoimmune disease, infectious disease,
allergic inflammations (such as asthma), and to prevent post-transplantation rejection6 ,7. Due to
low bioavailability - a result of high molecular weight, polarity, and rapid degradation in the
stomach 7'8 - no MAbs are currently administered orally. Instead, MAbs are delivered through
parenteral routes - typically intravenous infusion - that can require travel to a medical
practitioner7' 9. Though estimated to account for approximately 20% of the pharmaceutical
pipeline 0 , a major impediment to increased utility, practicality, and patient compliance with
MAb therapies is the need for highly concentrated formulations that would permit subcutaneous
injection in a patient's home.
MAbs tend to have a long elimination half-life on the order of days7 , though sufficient
therapeutic potencies of chimeric or humanized MAbs often require protein doses of hundreds of
milligrams due to low specific activties10'". The U.S. Food and Drug Administration (FDA),
however, does not permit subcutaneous injections of volumes over ~1.5 mL with a viscosity
exceeding -50 centipoise (cP)". Such a requirement is often difficult to meet since multi-
hundred-mg/mL protein solutions are typically very viscous. This thick consistency with a
strong resistance to flow makes concentrated protein formulations challenging to handle and
administer to patients. Hence lowering their viscosity is critical to harness the benefits of
protein-based pharmaceuticals.
Recently, new strategies toward the aforementioned goal, such as the addition of
hydrophobic salts or of molecular crowding agents 14' to concentrated protein solutions,
65
have afforded much reduced viscosities. An alternative promising approach is to replace
aqueous protein solutions with crystalline suspensions 1'1 . However, crystallizing antibodies is
unpredictable and time-consuming due to their high molecular weight, abundant glycosylation,
and structural flexibility3"0 . We overcome this drawback, and in this chapter demonstrate that
viscosities of suspensions in neat ethanol and numerous other organic solvents, made from an
amorphous powder of y-globulin (a model protein for monoclonal antibodies) or monoclonal
antibodies, are drastically lower than those of equally concentrated aqueous solutions.
B. Results and discussion
PEG nanosuspensions of y-globulin are more viscous than the corresponding solution
Typically, highly concentrated solutions of therapeutic proteins are very viscous making
injections difficult. Herein we have explored this phenomenon and methods of circumventing it
by employing concentrated suspensions of amorphous protein powders, rather than conventional
aqueous solutions. Bovine y-globulin has been used as a model antibody in this study.
First, we investigated concentration dependence of the viscosity of aqueous solutions of
y-globulin. As seen in Fig 4-1, we observed the expected13"17'" exponential (as opposed to linear)
rise in solution viscosity as protein concentration increased. At 300 mg/mL, for example, the y-
globulin solution viscosity at 25*C is 370 t 20 cP, far higher than that permitted for
subcutaneous injections. Using dynamic light scattering, we determined that the average
effective diameter of y-globulin molecules in this solution is 37 nm (Table 4-1). Protein
molecules in this solution must be in close proximity to each other, with an average
intermolecular distance of less than one third of a molecular diameter (based on a spherical-
shape approximation with a Stokes diameter of 10.5 nm for y-globulin' 9). The resultant intimate
intermolecular contacts and abundant hydrophobic and electrostatic interactions 13 create a strong
66
resistance to flow, or high viscosity. This high y-globulin concentration of 300 mg/mL was
selected for most of the subsequent study.
We next investigated PEG4000 - typically used in relatively low concentrations as a
macromolecular crowder10 , 4 , 5 ,2 0 - as a precipitating agent. Addition of 1% PEG4000 to a 300
mg/mL y-globulin solution produced a translucent mixture suggesting a nanosuspension (i.e.,
having a particle diameter comparable with a half of the wavelength of visible light). Indeed,
particle size analysis thereof by dynamic light scattering yielded a diameter of 110 nm (Table 4-
1). Henceforth, translucency was used as a tentative visual indicator of nanosuspension
formation.
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Figure 4-1. Concentration dependence of viscosities of solutions (circles) and suspensions (triangles) of
y-globulin at 250C. Solutions were prepared in de-ionized water to give a final pH of 6.0 and suspensions
using neat ethanol. The data points incorporate the standard deviations which, however, are smaller than
the symbols.
The viscosity of this PEG-induced nanosuspension was 530 cP, or 1.4-fold greater than
that of a y-globulin solution of the same concentration (Table 4-1). We determined that this
increase in viscosity was not due to irreversible denaturation or aggregation of the protein upon
precipitation with PEG; when the nanosuspension was diluted, thereby re-dissolving the protein,
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the average particle diameter dropped to 36 nm, i.e., the same as for y-globulin in the original
solution (Table 4-1).
Table 4-1. Viscosities at 25'C and protein particle sizes of 300 mg/mL y-globulin formulations in 20
mM histidine-HCl buffer (final pH 5.2).
Formulation Viscosity (cP) Particle diameter (nm)
Solution 370 17 37 6.1
Suspension formed by (1% w/v PEG4000) 530 ± 12 110 2.3
Dissolved suspension n.d. 36 1.7
Excipients reduce viscosity comparably in both y-globulin nanosuspensions and solutions
We previously ascertained that hydrophobic intermolecular interactions are largely
responsible for high viscosities of concentrated solutions of monoclonal antibodies 3 . To test this
possibility for y-globulin, we added cationic, anionic, non-ionic, or zwitter-ionic surfactants to its
PEG-induced nanosuspension to disrupt hydrophobic contacts. All tested surfactants slightly
lowered the viscosities of PEG nanosuspensions of y-globulin, with the most potent (non-ionic
Pluronic F68) affording a 30% drop (Table 4-2). A comparable viscosity-lowering effect,
however, was also observed for y-globulin solutions. Though marginal in magnitude and
certainly falling short of our ultimate objective, these effects suggest that hydrophobic
interactions do play a role in the high viscosities of concentrated solutions and nanosuspensions
of y-globulin.
To test whether another factor - electrostatic interactions - contributes to viscosity
increases in nanosuspensions, we added 1 M salts to weaken these ionic interactions. Both
increasing and decreasing viscosities were observed in PEG-induced nanosuspensions of y-
globulin depending on the salt (Table 4-3). Surprisingly, the addition of NaCl, recently reported
to greatly decrease the viscosity of monoclonal antibody solutions17 , raised the viscosity of the
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suspension some 2.5 fold. The effects of salt excipients on solution viscosity thus seem to be
both protein-dependent and not applicable to suspensions.
Table 4-2. Viscosities at 25*C of 300 mg/mL y-globulin solutions and 1% (w/v) PEG-induced
nanosuspensions in the presence of surfactants in 20 mM aqueous histidine-HCl buffer (final pH of 5.2)
Surfactant Viscosity (cP)a
Classification Compound (%w/v) Solution Nanosuspension
None 370 17 530 12
BKCb (0.15) Cationic 300 6.8 400 3.2
BKC (0.04) 310 3.6 390 2.0
SDSC (0.1) Anionic 320 1.7 400 2.4
Tween 80 (0.1) 340 3.4 480 3.1
Tween 80 (0.001) . 340+ 17 470+ 7.6Non-ionic
Pluronic F68 (0.06) 240± 1.0 400 4.9
Pluronic F68 (0.01) n.d. 380+ 12
CHAPSd (1.2) Zwitterionic 320 3.8 410 6.1
CHAPS (0.3) n.d. 440 11
n.d. = not determined
a The surfactants themselves, even at the highest concentrations used, made negligible contributions to
observed viscosities. The p-values reflecting the viscosity differences between solutions and the corresponding
nanosuspensions were in all cases no greater than 0.01. The same applies to the viscosity differences between
the nanosuspension without surfactant and those with surfactants, except that in this case no p-value exceeded
0.03.
b Benzalkonium chloride
C Sodium dodecyl sulfate
d 3-[(3-Cholamidopropyl)dimethylammonio]-l-propanesulfonate
Among the other salts, addition of arginine-HCl (a common pharmaceutical additive8 )
showed the most potent viscosity reducing effect, decreasing the viscosity of a 300 mg/mL y-
globulin nanosuspension 6-fold (Table 4-3). As seen in the table, ethanolamine-HCl and Tris-
HCl were also quite potent, reducing viscosity 3.8- and 4.1-fold, respectively. Although these
hydrochlorides substantially decreased y-globulin nanosuspension viscosities, their effect on a
300 mg/mL protein solution was equally beneficial (Table 4-3), thus making formation of
nanosuspensions superfluous.
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Table 4-3. Viscosities at 25*C of 300 mg/mL y- Table 4-4. Viscosities at 25*C of 300 mg/mL y-
globulin solutions and 1% (w/v) PEG-induced globulin solutions and 1% (w/v) PEG-induced
nanosuspensions in the presence of various 1 M nanosuspensions in the presence of various 1 M
salts in 20 mM aqueous histidine-HCl buffer arginine salts in 20 mM histidine-HCl buffer
(final pH of 5.2). (final pH of 5.2).
Salt Viscosity (cP) . Anion Viscosity (cP)Nanosuspension Solution Nanosuspension Solution
None 530 12 366 ±17 None 530 ±12 366 ±17
Arginine-HCl 89 1.6 89 ± 0.30 CH 3COO~ 80 ± 9.5 121 ± 13
Tris-HCl 130 2.1 110 ±5.3 Cl- 89± 1.6 89 0.30
NH2(CH 2)20H HCl 140 4.5 150 ± 17 N0 3  89± 4.2 94 3.2
Guanidine-HCl 280 ± 3.1 n.d. Succinate 100 ± 2.6 
130 ± 4.3
Fumarate 105 ±5.2 100 ±4.9NH4C1 390±35 n.d. HO ~ 10 1ndHCOO- 110 11 n.d.
NaNO3  540 6.0 n.d. CF3COO~ 110 7.9 n.d.
KC1 770 ± 24 n.d. Camphorsulfonate 140 1.0 n.d.
L-Lysine-HCl 780 32 n.d. CH 3CH 2COO- 150 11 n.d.
D-Lysine-HCl 880 23 n.d. S042 160 0.13 n.d.
NaCl 1300 60 n.d. Citrate 180 3.7 n.d.
CH3COONa 1500 230 n.d. Glutamate 210 17 n.d.
n.d. not determined n.d. not determined
We then investigated effects on viscosity due to the nature of the anion in arginine salts.
As seen in Table 4-4, analog arginine acetate was the most effective, reducing nanosuspension
viscosity 6.6-fold. In fact, it is one of only two salts affording PEG-induced y-globulin
nanosuspensions that are less viscous than the corresponding solution (Table 4-4). Overall,
however, we continue to observe the same general trend: even when modification of PEG-
induced aqueous nanosuspensions with surfactants or salts lowered viscosity, the effect was
comparable to that achieved by adding the same excipients to a protein solution.
We therefore explored still additional precipitating agents. 0.43 M sodium citrate2 0
formed a translucent nanosuspension of y-globulin with a viscosity of 770 cP and an average
particle diameter of 120 nm (Table 4-5). However, this viscosity was higher than that of the
corresponding solution. In aqueous ethanol, a common system for precipitating proteins2 1 2 2 , a
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translucent nanosuspension with particle diameter of 100 k 9.9 nm formed in a 50% (v/v)
solution. Curiously, however, ethanol-induced nanosuspensions formed only at low protein
concentrations such as 15 mg/mL, but had a 5-fold higher viscosity than the corresponding
solution (Table 4-6). Thus, as with sodium citrate, a solution is again less viscous than a
nanosuspension.
Table 4-5. Viscosities at 25'C and protein particle sizes of 300 mg/mL y-globulin solutions and
nanosuspensions (induced by 0.43 M Na citrate) in 20 mM aqueous histidine-HC buffer (final pH of 5.2).
Formulation Additive Viscosity (cP) Particle Diameter (nm)
Solution 370 17 37 6.1NoneNanosuspension 770+ 33 120 3.7
Solution 120 13 n.d.
Nanosuspension 1 M Arginine acetate 110 3.7 n.d.
n.d. = not determined
Table 4-6. Viscosities at 25*C and protein particle sizes of a 15 mg/mL y-
globulin solution and ethanol-induced nanosuspension in 20 mM aqueous
histidine-HCl buffer (final pH of 5.2).
Formulation Viscosity (cP) Particle Diameter (nm)
Solution 4.0 0.14 21 0.45
Nanosuspension 20 0.10 110 + 9.9
Ethanolic suspensions of y-globulin are less viscous than solutions
Protein nanoparticles comprise a bimodal population: those protein molecules buried
within the particle and those on the surface. Decreasing the fraction of exposed protein
molecules should reduce viscosity. When formed with sodium citrate, PEG, or ethanol,
nanoparticles have a mean diameter of 113 nm (Tables 4-1, 4-5, and 4-6). A straightforward
calculation (for an idealized spherical nanoparticle with a diameter of 113 nm composed of
idealized spherical protein particles with a diameter of 37 nm, all but one protein molecule will
be on the surface: 113 nm - 2 x 37 nm = 39 nm; in other words, the nanoparticle contains
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essentially three protein molecules across) reveals that the vast majority of the protein molecules
in particles of this size are on the surface. Hence such nanoparticles fail to effectively shield a
significant fraction of y-globulin molecules. In contrast, simple geometrical considerations
predict that forming larger protein particles should (i) increase the fraction of protein molecules
shielded in the interior and (ii) substantially reduce the number of protein particles in suspension,
thereby increasing the free space available to each.
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Figure 4-2. Viscosities at 25'C of a 260 mg/mL aqueous solution and aqueous-ethanol suspensions of y-
globulin. Solutions were prepared in 20 mM histidine-HCl buffer (final pH of 5.2) and suspensions using
neat ethanol.
We observed a dense and opaque suspension when high concentrations of y-globulin
were precipitated in 80-100% (v/v) ethanol. These suspensions are thus comprised of particle
much larger than nanoparticles. Therefore, we further examined the dependence of suspension
viscosity on ethanol concentration. At 260 mg/mL, a y-globulin suspension in neat (i.e., 100%)
ethanol had the lowest viscosity: 15 t 0.81 cP (Fig 4-2). Importantly, this is 9-fold lower than the
viscosity of the corresponding aqueous solution of y-globulin.
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Examination of this y-globulin suspension in neat ethanol by light microscopy revealed a
wide distribution of particle sizes in the micron range, with a mean particle diameter of 8.9 pLm
(Table 4-7). In contrast to their much smaller counterparts discussed above, particles of this size
should display only a small fraction of their component protein molecules on the surface, most
being hidden in the interior of a particle. Additionally, such suspensions should have much
larger inter-particle distances compared to nanosuspensions, let alone solutions, of y-globulin.
Table 4-7. Viscosities at 25*C and protein particle sizes of a 260 mg/mL aqueous solution (final pH of
5.2) and neat ethanol suspension of cold-ethanol-precipitated y-globulin.
Protein Preparation Viscosity (cP) Particle Diameter (um)
Solution Suspension Mean Median
Commercial 150 2.5 15 0.81 8.9 6.1 7.06
Ethanol-precipitated 140 ± 10 16 1.3 9.6 6.7 8.06
a Upon a 10-fold dilution, the distribution of particle sizes did not change (data not shown).
Enzymic proteins are remarkably stable when suspended in neat organic solvents23 , and
we confirmed this principle for y-globulin suspended in absolute ethanol. After removing the
solvent under vacuum, and dissolving the dried protein powder in water, we measured that the
original and post-suspension solution viscosities were similar, suggesting that under these
conditions the protein suffers no irreversible solvent-induced unfolding and/or aggregation.
Figure 4-1 depicts the dependence of viscosity of y-globulin suspensions in neat ethanol
on protein concentration. The greatest drop in viscosity compared to the corresponding aqueous
solution, 16-fold, is achieved at 300 mg/mL, the highest protein concentration examined.
Therefore, though at all concentrations the viscosity of y-globulin suspensions is lower than that
of the solution, the higher the concentration the greater the advantage of suspension (Fig 4-1).
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Enhancements in viscosity were also observed under certain temperature conditions. As
the temperature was lowered from 250 to 10*C, viscosities of 260 mg/mL solution and ethanol
suspension increased 3.0 and 1.7 fold, respectively (Fig 4-3). The same pattern holds for 300
mg/mL y-globulin formulations, where solution and suspension viscosities at 25*C were 370 *
17 cP and 23 e 2.3 cP, respectively. At 17*C, the solution viscosity rose 1.8 fold, while that of
the suspension increased only 1.3 fold (Fig 4-3). Therefore, maximal viscosity benefits from y-
globulin suspension in ethanol are observed at low temperature and high concentration.
500 800
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Figure 4-3. Temperature dependence of viscosities of y-globulin suspensions of two different
concentrations in neat ethanol measured at 100C (black bars), 17*C (gray bars), and 25*C (hatched bars).
Thus far, all y-globulin formulations were prepared from the solid protein as obtained
from the manufacturer. Ideally, however, we would prepare y-globulin powders in-house to
control the process and ensure reproducibility. Therefore, we used cold-ethanol precipitation (a
rapid isolation method widely used for antibody purification21 2 2 ), to prepare y-globulin powder
from the commercial one. As seen from the data in Table 4-7, cold-ethanol precipitation appears
to cause no permanent damage; the resultant protein possessed nearly the same aqueous solution
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and ethanol suspension viscosities as the commercial y-globulin powder. Additionally, y-
globulin particle size in the resultant suspension (Table 4-7) was similar to that seen when a
suspension was prepared from the commercial protein.
Hydrogen-bonding properties of organic solvents impact y-globulin suspension viscosity
We next investigated the generality of our finding using the aforementioned cold-ethanol-
precipitated y-globulin. Suspensions of lysozyme in organic/oil mixtures were previously shown
to produce low-viscosity formulations , although their viscosities were not directly compared
to those of aqueous protein solutions. Here we selected over a dozen relatively simple neat
organic solvents, and measured the viscosities of a 260 mg/mL suspension of y-globulin in each
of them (as well as the viscosities of the solvents themselves). As seen in Table 4-8, most of
these protein suspensions were far less viscous than a y-globulin solution in water. The
tetrahydrofuran suspension had the lowest viscosity overall of only 3.6 cP: a 38-fold reduction
compared to protein solution (Table 4-8). While tetrahydrofuran is not FDA-approved as a
component of drug formulations, isopropanol is2 5 ; its 260 mg/mL y-globulin suspension had 18-
fold reduced viscosity compared to the corresponding protein solution.
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Table 4-8. Viscosities at 25*C of 260 mg/mL suspensions of ethanol-precipitated y-globulin in various
neat organic solvents.a
Number of hydrogen atoms Solven Viscosity (cP)
available for H-bonding EtOH-precipitated powder Solvent itself
1 3.6 0.003 0.32 0.01
2 5.8 0.50 0.46+0.10
3 6.3 0.70 0.49 ± 0
4 7.5 0.24 0.33 ± 0.004
5 7.7 1.6 2.2 ±0.11
<1 6 8.1 1.3 1.9 0.050
7 12 1.0 0.40 0.010
8 14 1.6 1.72 0.03
9 15 0.89 0.87 0.010
10 16 1.3 1.1 0.12
11 25 2.0 0.61 0
12 26 1.0 7.8 0.36
Water 140± 10 0.90+0.010
2 13 160 6.5 48 0.23
14 200 1.0 43 0.10
15 240 23 55 1.5
a The data for water has been included for comoarison.
b The following solvents are FDA approved for use in IM/IV pharmaceutical formulations: 2, 5-6, 10, 12-14,
and of course water. The remaining solvents are not approved for use (Ref 25).
Inspection of the data in Table 4-8 suggests that the viscosity roughly relates to the
hydrogen-bonding ability of the solvent. Suspensions in those solvents (Fig 4-4) that are unable
to donate a hydrogen atom for hydrogen-bonding (i.e., ethyl acetate, N-methylpyrrolidone, and
toluene) or that possess only one such hydrogen (isopropanol, ethanol, and methanol) as a group
have the lowest viscosities. Conversely, suspensions in solvents that contain two hydrogen
atoms available for H-bond donation (PEG200, propylene glycol, 1,4-butanediol) all have
viscosities over 6-fold higher. Thus, it appears that suspension in those solvent molecules that
form the most extensive hydrogen-bonding with protein particles result in the greatest suspension
viscosity; this rationale also applies to an aqueous solution of y-globulin.
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A recent publication 26 however, reported an opposite conclusion for three monoclonal
antibodies suspended in miglyol, benzyl benzoate, and/or ethyl lactate (even though they
observed no viscosity reduction benefits from suspending monoclonal antibodies in them). This
difference is likely due to the fact that all three solvents tested were esters, thus providing little
chemical diversity. The same conclusion applies to another 2012 publication.
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Figure 4-4. Chemical structures of organic solvents in which antibody powders were suspended.
Tetrahydrofuran (1), ethyl acetate (2), toluene (3), acetonitrile (4), isopropanol (5), N-methylpyrrolidone
(6), methyl ethyl ketone (7), benzyl acetate (8), decane (9), ethanol (10), methanol (11), benzyl benzoate
(12), PEG 200 (13), propylene glycol (14), and 1,4-butanediol (15).
Viscosities of pharmaceutical antibody suspensions are also reduced in neat solvents
Murine, chimeric, humanized, and human IgG monoclonal antibodies comprise the
majority of clinically validated therapeutics and experimental proteins 2. Lastly, we explored
the generality of the benefits of neat organic solvent suspensions (as presented in Table 4-8) by
using a murine monoclonal antibody made at the pharmaceutical company Sanofi-Aventis
(SMAb) and a humanized monoclonal antibody made at Novartis (NMAb). We first prepared a
protein powder by concentrating and lyophilizing a SMAb solution. This dense solid was then
milled to a fine powder in liquid nitrogen to minimize putative protein damage resulting from
heat and/or moisture. Lyophilized powder dissolved rapidly in water and the resulting solution
had increased viscosity, as expected, but showed no increase in protein particle diameter. After
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concentration and liquid-nitrogen milling, SMAb powder again dissolved rapidly in water,
though a portion of the solid was entirely insoluble.
An aqueous solution of the milled SMAb at 200 mg/mL had viscosity of 14 t 0.75 cP
(Table 4-9), very close to the 12 t 0.14 cP for a solution of the non-milled powder (i.e., a SMAb
solid obtained from direct lyophilization of the original 8.6 mg/mL solution). This suggests that
the soluble milled protein was not damaged or aggregated as a result of liquid nitrogen milling.
Aggregation or unfolding could be particularly problematic with therapeutic antibodies as these
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changes decrease affinity and increase the incidence of immunogenicity in vivo2. We then
suspended this milled SMAb powder in toluene - a solvent that gave one of the lowest
suspension viscosities in y-globulin studies (Table 4-8) - at the same 200 mg/mL concentration.
The toluene suspension viscosity was 4.9 ± 0.68 cP (Table 4-9), 2.5-fold reduced from the
solution.
Table 4-9. Viscosities at 25*C of aqueous solutions of SMAb (120 mg/mL, final pH of 5.2) and
NMAb (150 mg/mL, final pH of 6.1), and SMAb and NMAb suspensions in neat toluene or ethanol,
respectively.
Protein preparation Viscosity (cP)
SMAba NMAbb
Solution 12 0.14 74 2.4
N2-Milled MAb solution' 14 ± 0.75 86 ± 4.0
N 2-Milled MAb suspensionc 4.9 ± 0.68c 11 * 1.5
a SMAb was formulated at 120 mg/mL in sodium citrate buffer or toluene. It was not possible to
examine more concentrated preparations because solid MAb at 200 mg/mL comprised almost the entire
volume of the suspension in organic solvents. A minor portion of the milled SMAb was insoluble in
water, presumably due to irreversible aggregation. Protein concentration was determined by measuring
absorbance at 280 nm.
b NMAb was formulated at 150 mg/mL in histidine-HCl bufer or ethanol.
"N2-milled" refers to solid MAb obtained by milling in liquid nitrogen.
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A second, humanized MAb was obtained from the pharmaceutical company Novartis and
at a concentration of 150 mg/mL had a viscosity of 74 - 2.4 cP (Table 4-10). When lyophilized
and milled, the viscosity of an ethanolic suspension of this NMAb was 8.5-fold less than that of
the corresponding solution. Both MAbs demonstrate the same trends: 1) fine and homogenous
powder forms low viscosity suspensions and 2) suspension in either hydrophilic or hydrophobic
solvents decreases formulation viscosity.
Conclusion
In this work, we successfully endeavored to lower the viscosities of concentrated
antibody formulations by switching from solutions to suspensions of amorphous powders.
Methods to prepare low-viscosity suspensions of the model protein y-globulin and full-length
murine and humanized MAbs in organic solvents were elaborated and validated. Protein-protein
and protein-solvent hydrophobic, electrostatic, and hydrogen-bonding interactions were
identified as critical in the observed viscosity reductions. By suspending protein powders in
organic solvents possessing one or no hydrogen atoms available for H-bonding, we prepared
highly concentrated but still non-viscous antibody formulations.
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C. Materials and Methods
Chemicals
Monoclonal antibody designated herein as SMAb was kindly provided by Sanofi-Aventis
Company (Frankfurt, Germany). The 147-kDa murine SMAb with an isoelectric point of 6.6
was supplied at 8.6 mg/mL in 10 mM citrate buffer (pH 5.5). Monoclonal antibody designated
herein as NMAb was kindly provided by Novartis Pharma AG (Basel, Switzerland). Properties
of the humanized NMAb can be found in Reference 7, where it is designated as "MAb 1".
Bovine y-globulin (product #G5009), other reagents, and most solvents were purchased from
Sigma-Aldrich Chemical Co. (St. Louis, MO); absolute ethanol was from VWR International
(Radnor, PA).
Viscometry
Viscosities were measured using a Brookfield DV-II Pro viscometer equipped with a
cone-and-plate geometry, a CPE 40 or CPE 52 spindle, and a temperature-controlling water bath.
The viscometer was pre-calibrated using a CAPOL standard (supplied by Brookfield) and water.
Measurements were performed with 500-pL samples in the "external" mode, where increasing
shear rates equivalent tolO%-100% of instrument torque (from 3.0 to 53 s-1 and 23 to 200 s-1)
were used, depending on viscosity. The viscosity values reported herein are an average of at least
duplicate measurements taken at 25*C unless stated otherwise. Plots of viscosity vs. shear rate
were typically non-linear, characteristic of non-Newtonian pseudoplastic solutions and
suspensions29 (Fig 4-5A); however, such solvents as ethanol and ethyl acetate, when measured
alone as controls, exhibited ideal Newtonian behavior (Fig 4-5B). All protein formulations
exhibited a non-Newtonian dependence, as expected for concentrated solutions and colloidal
suspensions 0'31. The resultant plots were extrapolated to zero-shear values from the highest
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13,29three shear rates1 . Apparent viscosities calculated from these linear extrapolations were
accepted when the R2 exceeded 0.9529
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Figure 4-5. Sample plots of viscosity vs. speed for a non-Newtonian SMAb solution (A) and Newtonian
organic solvent ethyl acetate (B).
Dynamic light scattering
Particle diameters of y-globulin nanosuspensions were measured using a DynaPro
NanoStar Light Scattering instrument from Wyatt Technology (Santa Barbara, CA) in the
dynamic light scattering mode. Measurements were performed in duplicate according to
manufacturer's instructions in a quartz cuvette at a laser wavelength of 658 nm. Particle
diameters were determined using % mass analysis. Typically, the population of interest
comprised >98% by mass for dilute formulations and >93% by mass for concentrated
formulations.
Light microscopy
Particle diameters of micron-sized y-globulin suspensions were measured using a Zeiss
Axioplan II upright microscope with a halogen transmitted light source. Images were collected
with a Qimging color camera at 10- and 25-fold magnifications. A protein suspension in 2 PL of
ethanol was smeared across a glass microscope slide, quickly covered with a No. 1 glass cover
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slip and immediately sealed with nail polish to prevent evaporation of ethanol. ImageJ software
was used to determine the average diameter of ~200 protein particles per sample.
Preparation of y-globulin solutions, suspensions, and nanosuspensions
y-Globulin aqueous solutions were prepared at the desired concentration by adding water
or aqueous buffer to protein powder, followed by centrifugation at 1,300 x g for 60 min using an
Eppendorf 5810R centrifuge equipped with an A-4-81 rotor. Volume was adjusted as necessary:
for example, only 3.5 mL of water was added to 1.3 g of y-globulin to prepare 5 mL of protein
solution at 260 mg/mL. A stir bar was added, and the resulting mixture was gently shaken
overnight at room temperature to achieve complete dissolution of the protein. The pH of this
solution was 6.0 unless otherwise indicated. Subsequently, the y-globulin solution was
centrifuged at 500 x g for 10 min to remove air bubbles prior to viscosity measurements.
To make protein nanosuspensions using such precipitating agents as 4,000-Da
poly(ethylene glycol) (PEG4000), a solution of y-globulin was prepared with a final volume
below 5 mL. PEG4000 was then added to the desired concentration (w/v), and the mixture at
room temperature was gently stirred for 1 h to dissolve the PEG4000, and centrifuged at 500 x g
for 10 min to remove air bubbles. Volume was then adjusted as necessary.
An analogous protocol was used to make aqueous suspensions with ethanol: To prepare
aqueous ethanolic suspensions of y-globulin, neat ethanol was added to a concentrated y-globulin
solution prepared as described above to give a final ethanol concentration in the range of 80-95%
(v/v) and a final y-globulin concentration of 260 mg/mL.
To prepare y-globulin suspensions in neat organic solvents, the latter was added to
protein powder to the desired concentration (e.g., 5 mL to 1.3 g). The mixture was centrifuged at
1,300 x g for 10 min. A stir bar was introduced, and the suspension was tapped to release the
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thick protein pellet and stir bar. The resultant suspension was gently shaken for 3 h at room
temperature and centrifuged at 500 x g for 10 min. The volume was adjusted as necessary, and
the suspension was stirred for 5 min at room temperature to re-suspend protein particles before
viscosity measurements. The same viscosities were observed whether the suspension was
formed by adding solvent to y-globulin or vice versa.
Ethanol precipitation of y-globulin
Ethanol precipitation of y-globulin was performed in a cold room from a 260 mg/mL
protein solution prepared as described above with both liquids chilled to 4'C. The final ratio of
absolute ethanol to protein solution was 4:1 (v/v). The first portion of cold ethanol was added
drop-wise to a protein solution with vigorous stirring. The remaining three portions were added
in a slow stream. The resultant mixture was stirred for 10 min and filtered through a Corning
Disposable Sterile Filter System with a 0.22-[tm-pore polyethersulfone membrane. After 10
min, the collected solid (which should be slightly sticky but not wet) was disturbed and left on
the filter to dry. After another 5 min, the solid was transferred from the filter to a weigh paper
and dried for 1 h. During this drying step, the solid was repeatedly flattened and then scraped up
in order to help release trapped ethanol to result in a white, very fine, free-flowing powder.
Preparation of solid MAb
Solid SMAb was prepared from the buffered aqueous solution in which it was received
from Sanofi-Aventis by concentration, lyophilization, and liquid-nitrogen milling. First, it was
spin-concentrated to approximately 200 mg/mL in a 50-kDa MWCO Amicon Ultra-15 device
(EMD Millipore) with a regenerated cellulose membrane. The concentrated solution was flash
frozen and lyophilized for up to 48 h until dryness. A mortar and pestle were placed in a
crystallization dish and pre-cooled in liquid nitrogen. Solid SMAb was placed in the mortar and
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frozen for 10 min. Next, the protein was milled for 10 min; liquid nitrogen was added to the
mortar and dish as needed to prevent crystallization of water within the mortar and on the end of
the pestle. It is important to note that concentration and milling were necessary to form a protein
powder fine enough to suspend at high concentration. After milling, the suspended protein was
poured into a glass scintillation vial and covered with a Kimwipe T M to allow the liquid nitrogen
to evaporate. The solid SMAb was then stored at 4'C for short-term use. Solid NMAb was
prepared and stored analogously, with lyophilization directly from the provided solution.
Preparation of solutions and suspensions of MAb
Aqueous solutions were prepared by incrementally adding solid MAb powder to an
appropriate volume of water or aqueous buffer in a 1.5-mL Eppendorf tube (solvent was chosen
to give the same citrate concentration in all samples). The mixture was centrifuged in a VWR
Galaxy 7 Microcentrifuge at 1,500 rpm for 1 min and then gently shaken at room temperature
until near-complete dissolution occurred (typically 30-60 min). Additional powder was added
and the process repeated until the final concentration of protein - as determined by absorbance at
280 nm - was achieved.
To prepare MAb suspensions in neat organic solvent, protein powder was added to a 5-
fold (w/v) excess of solvent in a 15-mL Falcon tube. The mixture was centrifuged at 1,000 x g
for 10 min using an Eppendorf 5810R centrifuge equipped with an A-4-81 rotor and then gently
shaken for 1 h at room temperature. The protein was pelleted at 2,500 x g for up to 10 min and
the solvent aspirated. Fresh solvent was added to the desired concentration (as determined by the
total volume of the suspension: the sum of the volumes of liquid and the pelleted solid). The
powder was resuspended by gentle shaking for 5 min immediately prior to viscosity
measurements.
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(zanamivir derivative 11)
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3-Acetamido-2-(J-(((4-(aminomethyl)phenyl)carbamoyl)oxy)-2,3-
dihydroxypropyl)-4-guanidino-3,4-dihydro-2H-pyran-6-carboxylic
acid (14)
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3-Acetamido-2-(1-(((2-(2-aminoethoxy)ethyl)carbamoyl)oxy)-2,3-
dihydroxypropyl)-4-guanidino-3,4-dihydro-2 H-pyran-6-
carboxylic acid (13)
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Poly-L-glutamine derivatized with 5% zanamivir (12h)
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Zwitterionic polymer scaffold 16a: 2-methoxy-N,N,N-
trimethylethanaminium and free carboxylate side chains
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